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 Diabetes mellitus (DM), a disease with far-reaching cardiovascular and 
physiological consequences, continues to grow at epidemic proportions despite efforts by 
the medical community to manage the disease, placing an enormous financial burden on 
the healthcare system.  The Centers for Disease Control and Prevention released a report 
in 2014 reporting 29.1 million people in the United States have diabetes including 8.1 
million undiagnosed cases.  Colorado is one of eight states with the most significant 
increases in DM diagnoses, nearly doubling between 2003 and 2014.  An estimated 
300,000 adults have diabetes in Colorado and an estimated 110,000 more are 
undiagnosed (Colorado Department of Public Health and Environment, 2015). 
In the last three years, the American Diabetes Association (ADA; 2017), the 
World Health Organization (WHO; 2011b) and the U.S. Preventative Services Task 
Force (USPSTF; 2017) have released new recommendations on screening and diagnosing 
DM--all with nearly identical criteria; yet, these recommendations are rarely referenced 
or utilized.  Glycosylated hemoglobin A1c (A1c) and fasting glucose levels are the most 
widely recognized tests for screening and managing diabetes and are included in the 
screening recommendations for the three largest organizations.  To enhance the quality 
and consistency of diabetes screening practices in adults in the primary care setting, the 
iv 
 
purpose of this capstone project was to create a simple yet comprehensive clinical 
practice guideline utilizing fasting glucose levels and A1c as screening tests to aid 
providers at Park Avenue Medical Group in Ft. Lupton, Colorado. 
Two rounds of Delphi surveys were completed by expert provider participants to 
provide the foundation for the development of a clinical practice guideline in conjunction 
with current literature supported by the ADA (2017), WHO (2011b), and USPSTF (2017) 
and a retrospective study conducted as part of this research project.  Five providers 
responded to the first round of surveys and four responded to the second round to elicit 
over an 80% response rate on the utility, comprehensiveness, and practical use of a 
diabetes screening guideline and algorithm.  The results indicated a strong need for a 
discrete and comprehensive practice guideline. 
Data extracted from the retrospective study, literature review, and Delphi surveys 
were aggregated to develop the clinical practice guideline; through the use of the second 
Delphi survey, the guideline was refined to accommodate the provider participants’ 
recommendations.  In addition to the creation of a written guideline, an algorithm was 
designed that offered two clinical pathways depending on age to screen with an informal 
risk assessment and A1c at different intervals.  Additional recommendations outside the 
scope of this capstone project were included to conduct a second post-implementation 
retrospective study after an initial pilot period.  The Stetler (2001) model was used to 
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CHAPTER I  
 
 
STATEMENT OF THE PROBLEM 
 
 
Background and Significance 
 
Diabetes mellitus (DM) is a disease well known to the medical community.  
Despite continuous research efforts to manage the disease, it continues to grow at 
epidemic proportions, placing enormous financial burdens on the healthcare system.  The 
National Diabetes Statistics Report released most recently in 2014 by the Centers for 
Disease Control and Prevention (CDC), reported 29.1 million people in the United States 
have diabetes.  Included in that astronomical statistic was 8.1 million undiagnosed cases 
(CDC, 2014).  An estimated 28.9 million people with diagnosed and undiagnosed DM in 
the United States are over the age of 20 and it affects men more than women.  American 
Indians/Alaska Natives have the statistically highest incidence of all races and ethnicities 
at 15.9%, followed by non-Hispanic Blacks (13.2%), Hispanics (12.8%), and Asian 
Americans (9.0%); non-Hispanic Whites have the lowest rates at 7.6% (CDC, 2014).  In 
2012, over 1.7 million people over the age of 20 were newly diagnosed with diabetes and 
an estimated 37% or 86 million additional American adults are considered to have 
prediabetes based on fasting blood glucose or A1c levels.  Two-hundred and eight 
thousand individuals under the age of 20 carry a Type 1 or Type 2 DM diagnosis.  In the 
adolescent population, an estimated 23,525 individuals are diagnosed with Types 1 or 2 
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diabetes annually with increased incidence noted in the 10- to 19-year-old age group 
(CDC, 2014). 
In Colorado, there was a 55% increase in the incidence of DM, identifying the 
state as one of eight states with the most significant increase in cases in recent years--
growing from 4.7% in 2003 to 7.3% in 2014 (Colorado Department of Public Health and 
Environment [CDPHE], 2015).  Nearly 20,000 Colorado residents were newly diagnosed 
with DM in 2014 alone and over half of the diagnoses occurred in the 18- to 54-year-old 
age group.  Additionally in Colorado, an estimated 300,000 adults have a diabetes 
diagnosis along with an estimated 110,000 more undiagnosed (CDPHE, 2015).  Hispanic 
and Black individuals are nearly twice as likely to have diabetes compared to White 
individuals.  As age increases, the prevalence of DM also increases, while education and 
socioeconomic status are inversely related to a diabetes diagnosis.  Demographically 
speaking, southeastern Colorado has the highest diabetes prevalence, which is nearly 
twice the state’s average (CDPHE, 2015). 
Diabetes is a disorder characterized by a marked elevation of blood glucose levels 
resulting from abnormal insulin production.  Type 1 diabetes can be diagnosed at any 
age; however, it is typically diagnosed in the teens and occurs when the beta cells in the 
pancreas are destroyed by mediation or initiation of the body’s immune response.  The 
end result is limitation or elimination of insulin secretion, causing elevations in glucose 
levels.  Currently, Type 1 diabetes cannot be prevented and must be treated with insulin 
delivery via subcutaneous injection or intrathecal pump at regular intervals (CDC, 2014).  
Type 2 diabetes usually develops later in life and accounts for 90-95% of all diabetes 
diagnoses.  This type of diabetes begins with insulin resistance caused by dysfunction of 
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the cells within the muscles, liver, and fat tissues.  The beta cells lose their ability to 
produce sufficient quantities of insulin, causing a gradual rise in blood glucose levels 
over time (CDC, 2014).  Age, obesity, family history, physical inactivity, race/ethnicity, 
history of impaired glucose metabolism, or gestational diabetes are all risk factors for the 
development of Type 2 diabetes.  Type 2 diabetes is treated with diet, exercise, and oral 
and injectable glucose lowering agents; it may be reversible depending on cause (CDC, 
2014).  Prediabetes is diagnosed when an individual has elevations in blood glucose or 
glycosylated hemoglobin levels but not yet meeting the diagnostic criteria for diabetes.  
Prediabetes is the precursor to Type 2 diabetes and carries the same cardiovascular risk; 
however, it can be avoided through lifestyle modifications including weight loss, diet, 
and exercise (CDC, 2014). 
Diabetes is not only a disorder of blood glucose levels.  It is a vascular disease 
with far reaching and potentially devastating consequences including end-organ failure.  
Most affected individuals have one or several comorbidities such as hypertension, 
hyperlipidemia, obesity, cardiovascular disease, and kidney disease leading to heart 
attack and stroke, blindness, and amputations (CDC, 2014).  In addition to the 
comorbidities and complications mentioned, people with DM may develop neuropathies, 
non-alcoholic fatty liver disease, periodontal disease, hearing loss, and depression.  
Diabetes mellitus is the seventh leading cause of death in the United States.  It is 
suspected to be underreported as the actual cause of death in people with several 
comorbidities (CDC, 2014) and is the eighth leading cause of death in Colorado 
(CDPHE, 2015).  The risk of death among people with diabetes is almost twice as high as 
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individuals with similar risk factors who do not have diabetes (Deshpande, Harris-Hayes, 
& Schootman, 2008). 
Diabetic ketoacidosis (DKA) is a diabetes-related emergency characterized by 
hyperglycemia, hyperketonemia, and metabolic acidosis in extremely insulin deficient 
individuals.  Diabetic ketoacidosis is a major cause of DM related hospitalizations and 
can result in death (MacArthur, 2015).  Recent studies indicate DKA hospitalizations are 
increasing in the United States.  From 1996 to 2006, there was a 35% increase in the 
number of hospitalizations with DKA as the primary diagnosis (Palmiere, Bardy, 
Mangin, & Werner, 2013).  Causes of DKA have been attributed to errors in insulin 
dosing, undiagnosed DM, alcohol use, illness or infection, trauma, surgery, or steroid use.  
Diabetes is often initially diagnosed during a DKA related hospitalization (MacArthur, 
2015).  It is estimated approximately 15% of all children and 24% of children under five 
years of age are not diagnosed with DM until they are in DKA and over one-third of them 
had been seen by a doctor at least once prior to receiving diagnosis (MacArthur, 2015).  
Diabetic ketoacidosis is the most common cause of death in children and adolescents 
with Type 1 diabetes and accounts for half of all deaths in patients under 24 years of age 
with DM (Palmiere et al., 2013). 
Fulminant diabetes is a new subtype of Type 1 diabetes considered to be 
idiopathic in nature.  The clinical features include abrupt onset of ketosis or ketoacidosis 
and nearly absent C-peptide secretion along with elevated plasma glucose levels and 
almost normal HbA1c levels (Imagawa & Hanafusa, 2006).  This subset of DM is 
especially concerning because of the rapid onset of symptoms and higher potential for 
death.  Fulminant DM does not fit the usual clinical presentation of Type 1 diabetes 
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including childhood onset with elevated HbA1c levels and islet-associated antibodies.  
Individuals with fulminant diabetes often present to the emergency department (ED) in 
DKA with blood glucose levels over 1000 mg/dL on the day of onset with normal levels 
in the days prior to their admission (Imagawa & Hanafusa, 2006).  In a Korean study, the 
prevalence of fulminant DM in newly diagnosed patients with diabetes was reported to be 
7.1% and 30.4% among patients with adult onset diabetes (Palmiere et al., 2013). 
Diabetes is an expensive disease, costing the nation over $245 billion in 2012 
(CDC, 2014).  The average cost per patient per year in Colorado was over $13,000 
(CDPHE, 2015).  Medical expenditures for diabetes-related treatment is 2.3 times higher 
than those without a DM diagnosis (CDPHE, 2015).  One in every five healthcare dollars 
is directly attributable to diabetes with additional indirect costs associated with 
absenteeism, reduced productivity at work (presenteeism), and lost capacity to work 
(American Diabetes Association [ADA], 2013).  Forty percent of the total amount of 
healthcare expenditures related to DM were due to higher hospital admission rates and 
longer than average inpatient stays.  According to the ADA (2013), this is the single 
largest medical cost associated with DM.  Diabetic medications account for over a quarter 
of diabetes-related healthcare expenditures with the remainder of the costs associated 
with diabetes-related health resources, much of which is provided by Medicare.  As the 
diabetic population ages, the cost per person is expected to increase due to resource 







Screening for diabetes is currently performed through several methods--most 
commonly by fasting plasma glucose levels and glycosylated hemoglobin levels.  With 
the emergence of recent data, current screening methods would fail to detect DM in a 
large population of individuals including at-risk African Americans with low 
triglycerides and normal high-density lipoprotein (HDL) and A1c levels, individuals with 
hemoglobinopathies, and individuals with unrecognized fulminant diabetes.  Still 
troubling is the current literature suggesting DM is often unrecognized until a 
hospitalization following DKA, often resulting in death.  
A study by Corriere, Minang, Sisson, Brancati and Kalyani (2014) addressed the 
use of clinical guidelines for decision-making related to diabetes.  The authors concluded 
only 53% of queried providers used a guideline routinely, suggesting significant gaps 
exist in diabetes-related decision-making among providers.  Surprisingly, the study 
revealed a low level of diabetes- related knowledge among both providers who did and 
did not use a clinical guideline routinely.  The authors surmised this disparity as one 
reason guideline adherence was low.  Clinical guideline use is associated with greater 
diabetes-related knowledge and essentially better patient outcomes (Corriere et al., 2014).  
The purpose of this capstone project was to develop a simplistic clinical practice 
guideline to screen for DM in a primary care setting in an effort to facilitate early 
detection and initiate treatment to minimize diabetes-related complications and mortality 





The following research question guided this capstone project: 
Q1 In a primary care setting, how does guideline implementation to screen for 
diabetes mellitus compared to traditional screening techniques influence 
early detection in patients with previously undiagnosed diabetes? 
 
Theoretical Framework 
The high incidence of undiagnosed and underdiagnosed diabetes mellitus in the 
United States and locally in Colorado and the current methodology used to screen for 
diabetes demonstrate a lack of knowledge of significant risk factors beyond elevated 
glycosylated hemoglobin and plasma glucose levels in the primary care setting.  
Translating current research into practice is a necessary step to decreasing the morbidity 
and mortality related to diabetes or pre-diabetes diagnoses.  The Stetler (2001) model, 
originally developed in 1976, uses a step-wise, practitioner-oriented approach to research 
utilization by converting knowledge into practice through five phases: preparation, 
validation, comparative evaluation/decision making, translation/application, and 
evaluation. 
Phase I: Preparation 
The preparation phase of the Stetler (2001) model addresses the purpose, context 
and sources of research evidence.  During this phase, the purpose of the capstone project 
was acknowledged and internal and external factors were addressed.  The perceived 
problems were identified and prioritized and the research design was determined.  
Measurable outcomes were organized and Institutional Review Board (IRB) approval 
was obtained through the University of Northern Colorado prior to project 




Phase II: Validation 
The purpose of this phase was to focus on the utilization of the sources of 
evidence.  Within this phase, a comprehensive, systematic literature review was 
performed that identified the strength of the evidence presented in the project.  Resources 
were reassessed to address their applicability to improve current practices and non-
credible sources were eliminated.  A project without sufficient credible evidence would 
have been terminated during this phase of the Stetler (2001) model. 
Phase III: Comparative Evaluation/ 
Decision Making 
During Phase III of the Stetler (2001) model, the findings of the literature review 
were synthesized by identifying similarities and differences and an evaluation of the 
degree of evidence substantiation.  A decision was made about which evidence would be 
utilized for the capstone project (Stetler, 2001). 
Phase IV: Translation/Application 
The translation of the synthesized findings (recommendations) into practice was 
the focus of Phase IV (Stetler, 2001).  For the purposes of this project, a guideline was 
created using the data extracted from a retrospective chart review and the literature 
review.  The plan to disseminate the guideline was formalized during this phase and 
entailed providing the new clinical guideline to the providers at Park Avenue Medical 
Group (PAMG). 
Phase V: Evaluation 
Evaluation is the final phase of the Stetler (2001) model.  A formal appraisal of 
the clinical guideline implementation was evaluated for credibility, goal progress, and 
results.  Changes and recommendations were provided as considerations for future 
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studies (Stetler, 2001).  Phase V also appraised any unexpected or negative outcomes.  A 
cost-benefit analysis would be performed during this phase of the Stetler model; 
however, post-implementation evaluations were not conducted in this capstone project 
due to time constraints.  Figure 1 provides a visual representation of the Stetler model. 
 




The literature review was conducted to evaluate current diagnostic standards 
published by the ADA (2017), the U.S. Preventative Services Task Force (USPSTF; 
2017), and the World Health Organization (WHO; 2016).  The purpose of the 
investigation was to (a) evaluate gaps in diagnosis criteria utilized by three of the largest 
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research-based organizations with published diagnostic guidelines for diabetes and (b) 
establish congruency in diagnostic and screening techniques.  The following electronic 
databases were utilized for the literature review: the Cochrane Database Systematic 
Review, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Google 
Scholar, and PubMed.  Keywords included in the search were diabetes guidelines, 
diabetes in primary care, clinical guidelines, diabetes management, diabetes screening, 
screening criteria and diabetes diagnosis.  Criteria included full text articles published 
between 2009 and 2017 and written in the English language.  Study types were 
systematic reviews, meta-analysis, cohort studies, and randomized controlled studies. 
American Diabetes Association  
Guidelines 
The American Diabetes Association (Cefalu, 2017) released their 2017 Standards 
of Medical Care in January based on current literature and evidence-based practice (see 
Table 1).  Attempting to uphold the highest standards, the majority of their 
recommendations were based on A- or B-level evidence.  A-level evidence is derived 
from clear evidence from randomized controlled trials (RCT), compelling 
nonexperimental evidence, or supportive evidence from RCTs.  B-level evidence is 
derived from supportive evidence from cohort studies (Cefalu, 2017). 
The ADA (Cefalu, 2017) recommended several diagnostic tests for diabetes and 
prediabetes using fasting plasma glucose levels (FPG) or the two-hour plasma glucose 
value after a 75-gram oral glucose tolerance test or the glycosylated hemoglobin A1c 
criteria--all are equally appropriate for diagnostic testing (Cefalu, 2017, p. S12).  
Compared to A1c and FPG values, the two-hour plasma glucose value is predictive of 
more people with diabetes.  A1c levels have a convenience advantage over the other two 
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plasma glucose values and is less influenced by stress and illness--known precursors to 




American Diabetes Association Diagnostic Criteria for Diabetes 
Test Value Description  
Fasting Plasma Glucose ≥ 126 mg/dL Fasting is defined as no caloric 
intake for > 8 hours 
 
Two-hour Plasma Glucose ≥ 200 mg/dL Using WHO guidelines and glucose 
load of at least 75 g of anhydrous 
glucose 
 
A1c ≥ 6.5% Lab tested using method that is 
NGSP certified and standardized 
 
Random Plasma Glucose ≥ 200 mg/dL With classic symptoms of 
hyperglycemia 
Note. Repeat testing recommended unless clear clinical diagnosis present.   
 
Using the A1c level as a diagnostic tool, the ADA (Cefalu, 2017) recommends 
other factors also be taken into consideration.  The studies used to determine the A1c 
recommendations were based solely on adult populations; it is unknown if the same cut-
point should be used to diagnose DM in adolescents and children (Cefalu, 2017).  
Additionally, A1c levels may vary depending on race and ethnicity.  African Americans 
often have higher A1c levels than Caucasians after similar fasting and post glucose load 
levels, suggesting a higher postprandial glycemic burden (Cefalu, 2017).  Hemoglobin 
A1c levels might also be skewed in patients with abnormal red blood cell turnover or 
hemoglobinopathies such as pregnancy, sickle cell trait, hemodialysis, recent transfusion, 
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or erythropoietin therapy, suggesting interpretation of A1c levels in these individuals 
would be challenging.  Plasma blood glucose criteria should be used to diagnose DM in 
patients with abnormal red blood cell turnover (Cefalu, 2017).  The diagnosis of diabetes 
is made only after repeat confirmation unless there is a clear clinical diagnosis of random 
plasma glucose level ≥ 200 mg/dL in a symptomatic individual.  The second test should 
be conducted as soon as possible and questionable results should be repeated in 3-6 
months (Cefalu, 2017). 
Screening for diabetes is recommended in overweight or obese adults with one or 
more risk factors including A1c level ≥ 5.7%, impaired glucose tolerance (IGT) test, 
impaired fasting glucose (IFG) levels, a first-degree relative with DM, high risk ethnicity, 
women with past history of gestational diabetes, history of cardiovascular disease or 
hypertension, women with polycystic ovarian syndrome or other diseases causing insulin 
resistance, or physical inactivity.  The ADA (Cefalu, 2017) recommends routine testing 
for everyone beginning at age 45 and repeated every three years for individuals with 
normal results.  More frequent testing is recommended based on risk stratification and 
prediabetes status (Cefalu, 2017).  Children and adolescents who are overweight or obese 
and have at least two additional risk factors should also be tested for prediabetes using 
FPG, two-hour plasma glucose or A1c levels.  The ADA’s Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus defined a confirmed diabetes diagnosis 
if fasting or impaired plasma glucose levels were between 100 and 125 mg/dL.  This 
differs from the World Health Organization’s cutoff at 110 mg/dL (Cefalu, 2017). 
 The ADA (Cefalu, 2017) recommends Type 1 diabetes, also called immune-
mediated diabetes, be diagnosed using blood glucose levels rather than A1c.  
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Additionally, antibody screening is recommended in research trials or if a first-degree 
relative has Type 1 diabetes.  Type 1 DM is often diagnosed after a hyperglycemic crisis 
or life-threatening DKA.  It has been suggested that measuring islet antibodies in 
relatives of those affected by Type 1 DM might help identify individuals at risk for 
developing Type 1 diabetes before a hyperglycemic crisis or DKA event.  Type 2 
diabetes is much more insidious and frequently goes undiagnosed for several years.  The 
overall risk of developing cardiovascular complications is the same in undiagnosed as in 
diagnosed DM (Cefalu, 2017). 
A diagnosis of prediabetes is instrumental in the prevention or delay of Type 2 
diabetes.  The ADA (Cefalu, 2017) recommends yearly monitoring for the development 
of DM in individuals with a prediabetes diagnosis and intensive behavioral modifications 
to achieve and maintain a loss of 7% of initial body weight.  Additionally, the ADA 
recommends 150 minutes per week of moderate intensity physical activity augmented by 
technology assisted tools such as fitness applications, social networks, mobile diet 
tracking, and DVD-based content related to lifestyle modifications (Cefalu, 2017).  The 
diabetes prevention program (DPP) is an intensive lifestyle modification program, 
demonstrating a reduction in the incidence of Type 2 diabetes by 58% over three years by 
implementing the 7% weight reduction and 150 minutes per week of moderate intensity 
activities.  This is by far the strongest evidence presented in the prevention of Type 2 DM 
with numerous studies demonstrating sustained reduction in the conversion rate to DM 
(Cefalu, 2017). 
 Studies have demonstrated that reduction of caloric intake through quality of fat 
consumption rather than quantity has been contributory in preventing or delaying the 
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onset of Type 2 DM.  The Mediterranean diet--whole grains, nuts, berries, coffee, tea and 
yogurt--includes food items known to prevent Type 2 diabetes and are effective at 
lowering A1c levels (Cefalu, 2017).  Moderate intensity physical activity such as brisk 
walking improves insulin sensitivity and reduces abdominal fat in young adults and 
children.  Resistance training and breaking up prolonged sedentary time by walking has 
shown to moderately lower postprandial glucose levels in addition to reducing the risk of 
the development of gestational diabetes (Cefalu, 2017).  Pharmacologic interventions for 
diabetes prevention include oral glucose lowering agents such as metformin, 
pioglitazone, and exenatide, with metformin demonstrating the strongest evidence for 
long-term safety and efficacy.  Lifestyle modification and DPP were more effective than 
metformin but were costlier over a 10-year period (Cefalu, 2017). 
 Medications used in the treatment of diabetes include insulin for Type 1 diabetes 
and various oral and injectable agents for the treatment of Type 2 DM.  Initial therapy in 
Type 2 DM should include monotherapy with metformin unless the A1c is greater than 
9% in which dual therapy in indicated.  With individuals with blood glucose levels 
greater than 300 or A1c greater than 10%, combination injectable therapy is 
recommended.  A1c levels are checked at regular three- to six-month intervals and a 
stepwise approach to pharmacologic management is utilized until target A1c levels are 
met (Cefalu, 2017). 
World Health Organization  
Guidelines 
The WHO (2016) released new recommendations for the screening and diagnosis 
of diabetes after conducting their own systematic review of international literature 
available on the subject (see Table 2).  While the ADA’s (Cefalu, 2017) 
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recommendations seemed to mirror the WHO guidelines, several key points were 
emphasized in the WHO report.  Specifically, the WHO report analyzed the usefulness of 
the hemoglobin A1c as a diagnostic tool for the detection of Type 2 diabetes in the world 
population.  Currently, the WHO does not endorse the use of the HbA1c for the diagnosis 
of diabetes due to the limited availability of the test in many countries, its influence on 
hemoglobinopathies, and global inconsistencies in the A1c measurement (WHO, 2011b). 
 
Table 2 
World Health Organization’s Recommendations on Diagnostic Criteria for Diabetes 
Test Value 
Fasting Plasma Glucose  ≥ 7.0 mmol/L (126 mg/dl) 
Two-hour Plasma Glucose ≥ 11.1 mmol/L (200 mg/dl) 
HbA1c ≥ 6.5% 
Note. Adapted from The World Health Organizations Diabetes Recommendations (2016). 
 
The WHO (2016) guidelines, similar to the ADA’s (Cefalu, 2017) guidelines, 
based their recommendations on the quality of evidence using the grading of 
recommendations, assessment, development and evaluation (GRADE) methodology; 
however, feasibility and resources for low and middle-income countries were also 
considered.  The strength of the recommendations was based on a 2-point scale.  
Weak/conditional recommendations had a low, moderate, or high quality of evidence but 
were not applicable in lower resource countries.  Strong recommendations were moderate 
or high quality of evidence and were applicable in low resource settings (WHO, 2016). 
The WHO concluded the A1c level could be used as a diagnostic test for diabetes only if 
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stringent quality assurance processes were in place based on moderate GRADE quality of 
evidence and conditional strength of recommendations.  The A1c cut point for a diabetes 
diagnosis was 6.5%.  Unlike the ADA’s recommendations, the WHO concluded there 
was insufficient evidence to make any recommendations on A1c levels below 6.5% 
(WHO, 2011a). 
The WHO’s (2016) recommendations included a statement regarding the 
diagnosis of DM in an asymptomatic individual.  The diagnosis should not be based on a 
single abnormal plasma glucose or A1c level.  A second test with values within the 
diabetic range is required for diagnosis according to WHO standards, using fasting, 
random, or oral glucose tolerance testing in a stringently controlled testing or lab 
environment.  Use of the same diagnostic test is recommended; however, if a different 
test is utilized, the results could be used to formalize a diabetes diagnosis.  Periodic 
retesting is recommended for individuals having a singular positive diagnostic test and 
negative second test until DM status is clear (WHO, 2016). 
U.S. Preventative Services Task Force  
Recommendations 
The U.S. Preventative Services Task Force (Siu, 2015) released their latest 
recommendations on screening for Type 2 diabetes in December 2015 (see Table 3).  
Their recommendations pertained to the adult population ages 40-70 who are overweight 
or obese and asymptomatic.  Like the ADA and WHO recommendations, the USPSTF’s 
recommendations are based on the level of evidence but do not consider the cost of 
providing the screening services to the public (Siu, 2015).  The USPSTF (2017) 
guidelines are based on grade B recommendations, suggesting high to moderate certainty 
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of beneficial health outcomes from the implementation of their guidelines (USPSTF, 
2017).   
 
Table 3 
U.S. Preventative Services Task Force Diagnostic Criteria for Type 2 Diabetes 
Test Value 
Hemoglobin A1c Level ≥ 6.5% 
 
Fasting Plasma Glucose Level ≥ 7.0 mmol/L 
≥ 126 mg/dl 
 
2-hour Oral Glucose Tolerance Test ≥ 11.1 mmol/L 
≥ 200 mg/dl 
Note. Adapted from Siu (2015).  
 
 
The USPSTF (Siu, 2015) recommendations to screen only adult patients ages 40-
70 who are asymptomatic and overweight or obese were based on their research, 
indicating the target population is at the highest risk for cardiovascular complications 
related to a diabetes diagnosis and would reap the most benefit from primary prevention 
through intensive risk factor modification.  Furthermore, the USPSTF acknowledged 
persons with additional risk factors such as family history of diabetes, history of 
gestational diabetes, polycystic ovarian syndrome, or persons of high risk ethnicities 
might be at risk for developing diabetes at a younger age or with a lower body mass 
index (BMI), and therefore recommend screening earlier for individuals with at least one 
of these risk factors (Siu, 2015). 
Screening tests recommended by the USPSTF (Siu, 2015) included the HbA1c, 
fasting plasma glucose level, or the oral glucose tolerance test.  Like the 
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recommendations of the ADA and WHO, the USPSTF recommended repeat testing with 
the same test on a different day to confirm a diabetes diagnosis.  Screening intervals for 
individuals with an initial normal glucose level is recommended every three years (Siu, 
2015).  The USPSTF additionally recommended performing an annual risk assessment to 
identify risk factors for abnormal glucose metabolism such as obesity, physical inactivity, 
smoking, hypertension, and hyperlipidemia; however, no recommendations were offered 
on screening individuals with multiple risk factors (Siu, 2015). 
 Based on the evidence collected by the USPSTF (Siu, 2015), intensive behavioral 
counseling interventions for individuals at increased risk for cardiovascular disease are 
beneficial for lowering overall cardiovascular risk.  These interventions are especially 
helpful in populations with hypertension, hyperlipidemia, and obesity, demonstrating a 
reduction in the specific risk factor values.  Interventions aimed at individuals with 
impaired fasting glucose levels or impaired glucose tolerance could prevent diabetic 
conversion.  Lifestyle interventions are more effective at reducing progression to diabetes 
than medications such as metformin (Siu, 2015). 
 The USPSTF (Siu, 2015) recommended sending patients with a BMI > 25 and 
additional cardiovascular risk factors to intensive behavioral counseling to promote 
cardiovascular health through healthy diet training and exercise programs.  Screening for 
lipid disorders should begin in men over the age of 35 and women over the age of 45, 
who also have an increased risk for heart disease.  Screening for hypertension should 
begin at age 18 and tobacco use assessed annually with cessation interventions offered as 




Comparison of the Three Organization’s  
Modalities and Other Considerations 
Clinical guidelines are intended to assist providers in the diagnosis and 
management of illness and disease processes.  The increased prevalence of diabetes, 
especially Type 2 diabetes, has created an urgent need for uniformity in the diagnosis and 
management of the disease.  Although the ADA (Cefalu, 2017), WHO (2016), and 
USPSTF (Siu, 2015) have minor and negligible differences in the diagnosis techniques 
for diabetes, all agreed early diagnosis and treatment minimize the cardiovascular 
complications of later stages of the disease.  A meta-analysis and systematic review by 
Khunti et al. (2015) evaluated screening methods for the diagnosis of Type 2 diabetes by 
examining response rates, positive outcomes at initial and intermediate screening stages, 
and yield rates using 1-step, 2-step, and 3-4 step processes.  Initial response rates were 
defined as the proportion of people who accepted the invitation to the screening study 
compared to the total number invited.  The yield rate was the number of newly diagnosed 
Type 2 diabetes cases compared to the total number screened using the oral glucose 
tolerance test (OGTT) or blood test.  Invasive versus non-invasive testing methods were 
evaluated for heterogeneity and sensitivity (Khunti et al., 2015).   
The findings from the Khunti et al. (2015) study indicated the number needed to 
detect a single case of diabetes using the OGTT (1-step process) decreased as the number 
of steps increased.  The 2-step screening strategies, where test subjects were screened for 
diabetes prior to the OGTT, had a higher initial response rate and yet there was no change 
in yield and response rates if a blood test was used as the initial screening step (Khunti et 
al., 2015).  Conversely, considering all methods, the number of individuals at high risk 
for diabetes or diagnosed with diabetes decreased as the number of steps in the diagnosis 
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process increased, indicating less people needed to have the OGTT when screening and 
retesting were used.  Khunti et al.’s meta-analysis was unable to compare screening 
strategies such as the HbA1c and random or fasting blood glucose levels utilized in the 2-
step and 3-4 step processes due to a lack of available qualified studies, suggesting a study 
limitation or identified area for further investigation. 
A similar study by Bowen, Xuan, Lingvay, and Halm (2017) evaluated the 
sensitivity and specificity of the ADA, WHO, and USPSTF guidelines.  Over 7,100 
participants met study criteria.  Seventy-eight percent of participants met the screening 
criteria using the ADA guidelines, 24% met the USPSTF screening guidelines, and 34% 
met the latest USPSTF screening guidelines (Bowen et al., 2017).  Bowen et al.’s study 
reported the ADA guideline’s sensitivity to detect undiagnosed diabetes was 99.2%; 
however, their specificity was only 23%, causing a 78% false positive rate.  The 
USPSTF’s guideline criteria had a 76.7% specificity rate and 41.9% sensitivity rate while 
the WHO guideline had a 67% specificity rate and 65% sensitivity rate (Bowen et al., 
2017). 
The results of the Bowen et al. (2017) study suggested screening all participants 
with a random blood glucose level ≥ 100 mg/dL would screen an additional 23% of 
adults in the sample.  This statistic was based on literature suggesting a single random 
glucose level ≥ 100mg/dL was more predictive of undiagnosed DM than traditional risk 
factors (Bowen et al., 2017).  Identifying individuals with higher risk for the development 
of diabetes could be achieved by lower random glucose cut points creating higher 
sensitivity while higher cut points would create greater specificity.  Utilizing a random 
glucose level ≥ 100 mg/dL would achieve balanced sensitivity and specificity in detecting 
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undiagnosed DM.  A case-finding strategy was utilized to identify individuals with a 
random glucose level ≥ 100mg/dL; the authors concluded it would screen half as many 
people as the ADA and USPSTF guidelines to correctly identify one person with 
undiagnosed diabetes, thus maximizing case yield and minimizing unnecessary screening 
costs (Bowen et al., 2017). 
Summary of a Systematic Review Using 
the U.S. Preventative Services Task  
Force Screening Guideline 
 
Selph et al. (2015) performed a systematic review of RCT, controlled trials, 
observational studies, and screening methods for Type 2 diabetes using the USPSTF 
recommendations to determine if health outcomes were improved in individuals with 
impaired fasting glucose levels or impaired glucose tolerance through screening and early 
intervention.  The meta-analysis of the selected studies discussed the results of several 
key factors.  Benefits of screening for diabetes versus no screening were evaluated to 
assess long-term cardiovascular mortality and all-cause mortality over 10 years, 
concluding screening was not associated with better outcomes or reduced cardiovascular 
mortality.  Similarly, screening did not reduce the risk for all-cause mortality in the 
studies surveyed.  The harms of screening were also evaluated, demonstrating increased 
short-term anxiety in the initial six weeks post screening for a new diagnosis of diabetes 
and no negative psychological effects after one year (Selph et al., 2015). 
Studies evaluating the treatment of USPSTF screen-detected IFG or IGT or early 
diabetes included in the systematic review suggested split support on the validity of 
lifestyle interventions for all-cause or cardiovascular risk reduction (Selph et al., 2015).  
One study out of China concluded a six-year lifestyle intervention was associated with 
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risk reduction in both categories after 23 years of follow-up, while other lifestyle 
intervention trials demonstrated no beneficial outcomes on all-cause or cardiovascular 
mortality (Selph et al., 2015).  Pharmacological interventions were also considered for 
USPSTF screened individuals with new onset diabetes of IGT or IFG levels with studies 
demonstrating few benefits or reduction in mortality rates from trials of glucose lowering 
agents over placebo (Selph et al., 2015).  Studies evaluating the harms associated with 
treating screen detected diabetes or IFG or IGT were reviewed, suggesting that compared 
to placebo, interventions could result in harm and included complications such as 
hypotension, hypoglycemia, withdrawal symptoms, and increased incidence of 
congestive heart failure (Selph et al., 2015). 
Intensive treatment options versus standard treatment were also evaluated in the 
systematic review, concluding no risk reduction with intensive treatment for a first fatal 
or non-fatal cardiovascular event; however, all-mortality and cardiovascular event rates 
were lower (Selph et al., 2015).  Intensive glucose lowering therapy was associated with 
risk reduction for non-fatal myocardial infarctions; yet management including goal 
HgbA1c levels between 6.0% and 7.5% resulted in no decrease for all-cause or 
cardiovascular mortality compared to less intensive methods of management (Selph et al., 
2015).  Intensive blood pressure management decreased risk for all-cause mortality 
according to one study but differing definitions of intensive therapy caused the trial to 
lose validity.  More recent studies evaluated in the systematic review suggested similar 
results with consistent risk reduction in all-cause and cardiovascular mortality when an 
angiotensin-converting enzyme inhibitor and diuretic were added (Selph et al., 2015).  
Harms caused by intensive treatment versus standard treatment were also considered in 
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the review, demonstrating low and imprecise rates of reported harm with multifactorial 
treatment.  Intensive glucose lowering treatments were associated with higher rates of 
hypoglycemia and other medication-related adverse events requiring hospitalization 
(Selph et al., 2015). 
The benefits of treating impaired fasting glucose and impaired glucose tolerance 
levels to delay or prevent conversion to diabetes were also evaluated in the systematic 
review (Selph et al., 2015).  The studies evaluated lifestyle and pharmacological and 
multifactorial interventions over six months to six years.  Lifestyle interventions were 
associated with decreased risk of conversion to a diabetes diagnosis in six of the studies 
reviewed.  Pharmacological interventions indicated thiazolinediones decreased 
progression to diabetes as well as combinations of valsartan and low dose metformin and 
rosiglitazone (Selph et al., 2015).  Nateglinide and glimepiride were not associated with 
risk reduction for progression to diabetes.  Multifactorial approaches to prevent 
progression included glucose, blood pressure (BP), and lipid control in addition to 
lifestyle modifications; aspirin demonstrated a statistically significant decrease in the 
progression to diabetes in several of the studies evaluated in the systematic review (Selph 
et al., 2015). 
Diabetes Guidelines in Clinical Practice 
Underutilization of diabetes guidelines in the primary care setting is challenging 
and multifactorial.  According to Bouchonville, Matani, DuBroff, and DuBroff (2017), 
published guidelines often exclude relevant studies or are not evidence-based, causing 
confusion and discord in diabetes management and leading to low provider adherence.  
Bouchonville et al.’s study evaluated studies that target traditional cardiovascular risk 
24 
 
factors in diabetic patients: anti-platelet therapy, blood pressure, glycemic and lipid 
control, and lifestyle interventions.  The results of their systematic review suggested the 
ADA’s recommendations regarding a Mediterranean diet, blood pressure, and glycemic 
control were truly evidence-based but had questionable evidence to support specific 
pharmacological therapies.  Additionally, the review suggested the ADA’s evidence to 
support the use of aspirin or other anti-platelet therapy or statins in the management of 
diabetes was inconsistent and contradictory (Bouchonville et al., 2017).  While 
Bouchonville et al.’s systematic review did not specifically pertain to the utilization of 
guidelines to screen and diagnose diabetes, it highlighted the confusion providers face in 
diabetes prevention, screening, and management.  A second systematic review (De 
Belvis, Pelone, Biasco, Ricciardi, & Volpe, 2009) evaluating diabetes management 
guidelines surveyed over 1,700 abstracts and found only 13 articles suitable for their 
review and only one discussed guideline application and outcome/process indicators to 
evaluate delivery and adherence to evidence-based guidelines.  To aid providers in sifting 
through the abundance of literature, De Belvis et al. (2009) suggested educational/ 
training interventions, interactive technology, audit interventions or a combination of 
















The primary care setting is ideal for preventative health care, especially screening 
for diabetes and other diseases of chronicity.  Annual preventative or wellness visits are 
covered by nearly all health insurance plans and provide the opportunity to screen for 
diseases with far-reaching, end-organ, and cardiovascular consequences like diabetes.  
Recent changes in diabetes screening guidelines, lack of utilization, and absence of 
consensus on current screening practices provided an opportunity to intervene and create 
a clinical practice guideline to detect diabetes earlier in the primary care setting with the 
intention to screen individuals at the greatest risk or highest likelihood of reversibility 
through early diagnosis and treatment. 
The following four objectives for this capstone project included the creation of a 
diabetes screening clinical practice guideline to support congruency in screening 
practices based on the latest evidence-based literature: 
1. Gather information on current diabetes screening practices for the adult 
population at Park Avenue Medical Group.  The information was collected 
through a retrospective chart review evaluating screening processes and risk 




2. Survey a panel of expert providers within and outside Park Avenue Medical 
Group to assess gaps in screening processes and willingness to adopt a new 
diabetes screening guideline.   
3. Develop a diabetes screening guideline for providers to utilize during 
routine annual wellness visits based on the literature and consensus obtained 
through the survey. 




The setting for this capstone project was Park Avenue Medical Group (PAMG) in 
Fort Lupton, Colorado.  Park Avenue Medical Group is a small, privately owned practice 
comprised of one physician and one nurse practitioner providing services including acute 
and primary care; well examinations for men, women, and children; sports and 
Department of Transportation physicals; immunizations; minor surgeries; and 
laboratory/diagnostic testing.  Data from a retrospective chart review were gathered from 
the practice’s electronic medical record (EMR) from January of 2015 through June of 
2017. 
Sample 
The sample population investigated for the retrospective portion of this project 
included adult males and females between the ages of 25 and 60 who visited PAMG for 





As part of the fulfillment of the degree of Doctor of Nursing Practice (DNP), 
financial resources were not considered for this capstone project.  The retrospective study 
portion of the project was completed by this researcher utilizing PAMG’s electronic 
medical record. 
Phases 
Phase one.  The first phase of this evidence-based capstone project entailed the 
completion of a thorough literature review.  The results of the literature review indicated 
a strong need for congruency and compliance to a clinical practice guideline to aid 
providers in screening for diabetes in the primary care setting.  Included in phase one was 
the retrospective chart review, which was intended to extract data from the specified 
sample population.  Each chart reviewed was evaluated for ADA (Cefalu, 2017), WHO 
(2016), and USPSTF (Siu, 2015) risk factors, if screening was performed and the results, 
and for glucose levels over 100 mg/dL to improve sensitivity and specificity of the 
screening process.  In total, 709 charts were reviewed and 424 met all inclusion criteria. 
Phase two.  The second phase of the project was to create an evidence-based 
practice guideline.  The Delphi method was utilized to survey a panel of clinical experts. 
Data extrapolated from the survey were compiled and the researcher collaborated with 
the expert panel to develop the practice guideline.  Primary care providers for the expert 
panel included two physicians, two nurse practitioners, and one physician’s assistant 
within PAMG and in other practices outside of their organization.  Responses from the 
first Delphi survey questions in phase one helped identify methods currently utilized in 
primary care to screen for diabetes, risk factors identified by the providers, what 
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guidelines and recommendations were utilized, and specific tests performed in the 
screening process.   
Phase three.  During this phase, the clinical practice guideline was presented to 
the providers to review and modify.  Providers were educated on how to use the guideline 
and the guideline was evaluated using a second round of the Delphi method for proper 
utilization and compliance.  To promote consistency and preserve the integrity of the 
project, the same panel of five expert provider participants from round one of the Delphi 
survey was invited to participate in round two.  Four of the five providers completed 
round two of the survey.  The guideline was evaluated during this phase to ensure 
objectives were met. 
Phase four.  This phase entailed the physical implementation of the clinical 
guideline.  The guideline was provided to PAMG for utilization.  As previously stated, 
beyond presenting the guideline to the providers at PAMG, this phase was not completed 
during this capstone project. 
Project Timeline 
 The researcher utilized the following timeline for project phases: 
• Approval of phenomenon of interest--Fall 2016 
• Defend proposal (Chapters I-III of project) and obtain Institutional Review 
Board approvals from University of Northern Colorado (see Appendix A) and 
PAMG (see Appendix B)—June-July 2017 
• Retrospective chart review, initial Delphi survey and consent form sent (see 




• Development of clinical practice guideline and plan for implementation, 
second Delphi survey (see Appendix E), summary and responses (see 
Appendix F), finalize Screening for Type 2 Diabetes in Adults Guideline and 
Algorithm (see Appendix G), final defense of capstone project, and 
submission of completed capstone project to University of Northern 










EVALUATION OF PLAN 
 
 
In an effort to preserve consistency and integrity of this capstone project, each 
phase was evaluated through the following four objectives. 
Objective One 
The first objective was to gather information regarding screening practices for 
diabetes in the primary care setting.  This objective was accomplished through a 
retrospective chart review to evaluate current screening practices at PAMG on adult 
patients presenting in the clinic for wellness exams.  The data were analyzed for 
screening methods and risk stratification in diabetic and non-diabetic patients.  
Objective Two 
Objective number two was completed by surveying a panel of experts using the 
Delphi method to gather information on the utility of a clinical practice guideline.  The 
panel consisting of practicing physicians, nurse practitioners, and physician’s assistants 
was queried about current methods used for screening purposes, suggestions, and general 
knowledge to develop a provider friendly, evidence-based practice guideline. 
Objective Three 
The third objective was the development of the clinical guideline.  Information 
gathered from the review of evidence (literature review), retrospective chart reviews, and 
expert opinions were used to formulate the practice guideline.  Since the guideline was 
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intended to be utilized, special attention was paid to the consensus of expert opinions to 
achieve 70% consensus amongst the providers.  The panel of expert providers played an 
essential role in the development of the guideline by providing feedback on the feasibility 
and utility of the guideline.  A second Delphi survey was provided to the panel of experts 
once the guideline was completed; revisions were made to accommodate the 70% 
consensus goal on provider practices. 
Objective Four 
The fourth objective was the plan for implementation.  Physical implementation 
was not part of this capstone project; however, the staff at PAMG were trained on how to 
use the clinical practice guideline.  If the providers decided to use the practice guideline, 
it was recommended that a second retrospective chart review be performed to evaluate 
pre- and post-implementation results and make improvements as evidence changed or 













RESULTS AND OUTCOMES 
 
The purpose of this DNP capstone project was to evaluate current diabetes 
screening practices in the primary care setting and develop a clinical practice guideline to 
promote early detection and treatment of diabetes, thus minimizing long-term 
consequences and end organ damage caused by unrecognized and untreated DM.  The 
first objective of this project was to gather information regarding screening practices for 
diabetes in the primary care setting through a retrospective chart review on adult patients 
between the ages of 25 and 60 who presented to PAMG for annual wellness exams from 
January 2015 through June 2017.  Specifically, objective one was evaluating screening 
practices and risk stratification in both diabetic and non-diabetic patients.  Objective two 
utilized the Delphi method to survey a panel of experts in family medicine about current 
screening practices and the practical utility of an evidence-based clinical practice 
guideline.  Objective three included the development of a clinical guideline using 
information gathered from the review of evidence, retrospective chart review, and expert 
opinion.  A second Delphi questionnaire was administered to the panel of experts to 
complete this objective, which sought 70% consensus on the clinical utility and 
practicality of the guideline.  The fourth and final objective was the plan for 
implementation.  The physical implementation of the clinical guideline was not included 




Objective one was accomplished through a retrospective chart review conducted 
to evaluate data on adult patients between the ages of 25 and 60 who presented at PAMG 
for wellness exams during the period beginning January 1, 2015 and ending on June 30, 
2017.  The data were examined to quantify the number of diabetes-related risk factors in 
the patient population as well as analyze screening methods used for a wellness visit in 
diabetic and non-diabetic patients.  Candidates included in the chart review were either 
male or female from all races and ethnic backgrounds who presented to the clinic for a 
wellness physical where the International Classification of Disease (ICD) 10 code Z00.00 
(encounter for general adult examination without abnormal findings) or Z00.01 
(encounter for general adult examination with abnormal findings) was used (NuMed 
ICD-10 Lookup, n.d.).  To be included in the chart review, the patient must also have 
completed routine annual blood work ordered by the provider specifically in conjunction 
with the wellness visit.  Included blood work must have been completed within 30 days 
pre- or post-wellness visit and consist of at least a basic metabolic panel with an 
identified random or fasting glucose level.  
Materials and Methods 
Objective one was completed using the Aprima EMR application currently 
utilized by PAMG associates and providers.  Historical charts were reviewed beginning 
on January 1, 2015 and ending on June 30, 2017 on all patients presenting to the clinic 
for a wellness visit.  Charts on patients outside the ages of 25-60 or without routine 
wellness blood work consisting of a basic metabolic panel with a fasting or random 
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glucose level were eliminated from the study.  In total, 709 charts were reviewed; 285 
charts were eliminated, leaving 424 charts meeting all inclusion criteria. 
Each patient chart reviewed was assigned a unique identification number and was 
analyzed to document ADA (2017), WHO (2011b), and USPSTF (2017) diabetes-related 
risk factors including age, gender, ethnicity, body mass index, fasting or random glucose 
levels, hemoglobin A1c if available, history of diabetes, gestational diabetes, polycystic 
ovarian syndrome, cardiovascular disease, hypertension, and hyperlipidemia.  Initial data 
included all patients over the age of 25 meeting the aforementioned criteria; patients over 
the age of 60 were later omitted prior to the data analysis and were not included in any of 
the result statistics. 
Results 
The results analysis of the chart review reflected a total of 424 patients who 
visited PAMG for a physical during the selected time frame.  Of the 424 patients, 169 
were male (39.86%) and 255 were female (60.14%; see Figure 2).  The ethnic makeup of 
the selected patient population was derived from demographic information documented 
in the patient chart and included 318 White patients (75%), 101 Hispanic patients 
(23.82%), two Black patients (0.005%), and three Asian or Pacific Islander patients 
(0.007%; see Figure 3).  A total of 55 patients (12.97%) had a history of diabetes and 369 
patients (87.03%) had no recorded history of diabetes in their medical records (see 
Figures 4, 5, and 6).  Considering the risk factors identified by the ADA (2017), WHO 
(2011b), and USPSTF (2017), 78 patients (18.4%) had a BMI less than 25, indicating 
ideal or low body weight; 138 (32.55%) had a BMI between 25 and 29.9, falling in the 
overweight range; and 208 (49.05%) had a BMI falling in the obese range (see Figures 7 
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and 8).  One hundred patients or 23.58% of the queried patient population had a 
documented history of hypertension.  Two patients (0.005%) had a history of 
cardiovascular disease and 131 patients (30.9%) had a history of hyperlipidemia.  Of 
gender-specific risk factors, polycystic ovarian syndrome and gestational diabetes, only 
one patient was documented to have polycystic ovarian syndrome in their history, 










































Figure 3.  Racial and ethnic composition of surveyed population at Park Avenue Medical 






Figure 4.  Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus 
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Figure 5.  Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus 






Figure 6.  Surveyed patients with a documented pre-diabetes or diabetes diagnosis versus 
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Risk factors associated with a diabetes diagnosis were evaluated in 55 diabetic 
patients in the chart review process.  Surprisingly, none of the patients with diabetes had 
a documented history of cardiovascular disease.  Conversely, only 3.6% did not have any 
risk factors.  A BMI over 25 was the most significant risk factor in common with 96.4% 
of the diabetic patient population seen at PAMG, followed by hyperlipidemia (52.7%), 
hypertension (41.8%), and high-risk ethnicity (30.9%).  Of the 55 diabetic patients 
included in the chart review, over 81% of them had two or more risk factors (see Figures 
9 through 14).  
 
 
Figure 9.  Risk factors associated with a diabetes diagnosis in the population seen at Park 
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Figure 10.  Differentiation of risk factors associated with a diabetes diagnosis in the 
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Figure 14.  Patient population with polycystic ovarian syndrome or gestational diabetes 
by year.  
 
 
To improve sensitivity and specificity in the screening process, the data were 
analyzed to identify patients without an existing prediabetes, or diabetes diagnosis with 
and without fasting, or random glucose levels at or greater than 100 mg/dL.  In total, 28 
non-diabetic patients were identified as having blood sugars equal to or greater than 100 
mg/dL and have a hemoglobin A1c level falling in the diabetes or prediabetes range (at or 
above 5.7).  Interestingly, only five individuals were identified in 2015, 10 in 2016, and 
13 in the first six months of 2017.  These data suggested the providers identified these 
patients as “at risk” for diabetes and appropriately screened with a hemoglobin A1c.  An 
additional 15 patients were identified in 2017 with A1c levels falling in the diabetes or 
pre-diabetes range who had a fasting or random glucose level less than 100.  These 15 
patients were identified when the providers at PAMG began routinely screening with a 
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using the ADA (2017), WHO (2011b), and USPSTF (2017) screening guidelines.  Using 
Bowen et al.’s 2017 recommendation to screen all patients with a fasting or random 
blood glucose level equal to or greater than 100 mg/dL would have screened an 
additional 76 patients who were seen at PAMG for a wellness visit and did not carry a 
diabetes diagnosis.  Of the 76 identified patients, 39 were not screened with an A1c in 
2015, 33 were not screened in 2016, and only four were not screened in 2017 after the 
providers modified their screening practices to routinely include a screening A1c in the 
adult population, indicating routinely screening with an A1c would capture nearly 10 
times more patients with the potential to have an elevated hemoglobin A1c than 
screening with a fasting blood glucose alone (see Figure 15).  
 
 
Figure 15.  Non-diabetic patients with fasting plasma glucose levels over 100 mg/dL who 
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Objective One Outcome  
Statements 
This retrospective study was valuable for statistically describing the population 
seen by the providers at PAMG as well as to stratify the risks associated with diabetes in 
relationship to non-diabetic, prediabetic, and diabetic populations.  While many of the 
results paralleled the findings in the research offered by the ADA (2017), some of the 
results in the specific patient population at PAMG were not representative of the 
literature.  For example, the research presented by Bowen et al. (2017) suggested random 
blood glucose levels over 100 mg/dL were more predictive of undiagnosed DM than 
traditional risk factors; however, the retrospective study identified only 28 individuals or 
less than 7% of the selected population with fasting or random blood glucose levels ≥ 100 
mg/dL who had an A1c level falling within the diabetes or prediabetes range.  Although 
more closely related, out of the 106 individuals of a high-risk ethnicity, only 17 
individuals or 16% carried a diabetes diagnosis compared to 38 individuals or 11.95% of 
the sampled White population with diabetes, indicating a true increased propensity for 
individuals from a high-risk ethnicity to develop Type 2 diabetes mellitus. 
 The data examined in the retrospective study included the entire calendar year of 
both 2015 and 2016 and only six months of 2017.  The results extracted in each of the 
full years were statistically similar and it was anticipated the results for all of 2017 would 
also mirror the two previous years.  Early in 2017, the providers at PAMG changed their 
diabetes screening practices to include routinely screening adult patients with a 
hemoglobin A1c.  As previously stated, this change in procedure resulted in the 
recognition of 15 patients with fasting blood sugars under 100 mg/dL with A1c levels 
falling within the diabetes or prediabetes range.  In the absence of any other additional 
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risk factors recognized by the ADA (2017), WHO (2011b), and USPSTF (2017), this 
population of patients would not have been screened utilizing the existing 
recommendations, thus delaying interventions aimed at minimizing cardiovascular effects 
and end organ damage caused by diabetes.  Although respectively small, this group of 
patients is representative of the need for changes to the existing recommendations. 
The Reach, Efficacy, Implementation  
and Maintenance Framework 
The reach, efficacy, implementation and maintenance (RE-AIM) framework is a 
method used to analyze the strengths and weaknesses of interventions.  It can be used to 
plan new interventions, change existing interventions or evaluate the impact of 
interventions (RE-AIM, 2017).  The RE-AIM framework evaluates the reach of an 
intervention or the participation rate within the target population; the efficacy, which is 
the impact of an intervention on specified criteria; the adoption or percentage of 
representativeness of organizations adopting the intervention; the implementation, which 
evaluates the quality and integrity of the intervention in a clinical setting; and 
maintenance, which evaluates how well the intervention holds up long term (Glasgow, 
McKay, Piette, & Reynolds, 2001).  The practice of routinely screening adult patients 
with a hemoglobin A1c at PAMG was evaluated using the RE-AIM framework to 
evaluate the impact of the intervention introduced early in 2017. 
Reach.  The target population of the screening process initiated in 2017 was all of 
the adult patients who presented to PAMG for a wellness exam.  The providers, a medical 
doctor and a nurse practitioner, began screening all adults in the clinic for a wellness 
exam and also began screening patients with symptoms indicative of diabetes.  As a 
result, 15 patients were newly diagnosed with diabetes or prediabetes and were initiated 
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on antihyperglycemic agents or educated on lifestyle or behavioral modifications to 
promote risk reduction of diabetes related complications.  Additionally, the introduction 
of routinely screening adults resulted in a nearly10-fold decrease in the number of 
patients with a glucose level falling in the impaired fasting glucose range who were not 
previously screened with an A1c. 
Efficacy.  As previously stated, the impact of initiating the new diabetes 
screening practice resulted in the identification of patients with diabetes and prediabetes 
who would not have been screened using the ADA (2017), WHO (2011b), and USPSTF 
(2017) recommendations unless multiple risk factors were present.  Screening all adult 
patients with an A1c did indeed effectively screen more patients. 
Adoption.  Both providers at PAMG adopted the new screening practice, creating 
a 100% adoption rate.   
Implementation.  The degree to which the providers at PAMG consistently 
implemented the intervention on the desired population was difficult to determine by 
examining the data from the retrospective study alone.  Given the results of the study, 
screening more patients with an A1c did capture 15 patients with elevated A1c results 
falling within the diabetes or prediabetes range in the first six months, suggesting any 
degree of implementation improved patient outcomes. 
Maintenance.  Since the introduction of the diabetes screening practice using the 
hemoglobin A1c is in its infancy, more time is required to determine if the intervention is 
sustainable over a long period of time.  Given the perceived benefit of routinely screening 
adults with a hemoglobin A1c, it was anticipated the intervention would be sustained at 




The use of the hemoglobin A1c as a screening technique on adult patients with 
complaints suggestive of a diabetes diagnosis and as a routine intervention at wellness 
visits requires a simple and relatively inexpensive blood test.  Since many providers use 
routine blood testing to screen for a variety of conditions, it is reasonable to adopt the 
utilization of the A1c as a screening practice without inconveniencing patients for 
additional testing.  The obvious benefits include early interventions to modify behavior 
and reduce the cardiovascular effects and end organ damage caused by diabetes and 
elevated glucose levels. 
Other Considerations 
The data extracted from the chart review supported the need for more aggressive 
Type 2 diabetes screening and risk management.  The strongest data derived from the 
retrospective chart review supported the use of the hemoglobin A1c as the primary 
screening intervention for Type 2 DM.  The question of insurance reimbursement and 
coverage of the A1c test as a screening method remains at the forefront of discussions 
and promotes the underutilization of the A1c for screening purposes.  In a publication 
released by the Centers for Medicare and Medicaid Services (CMS) in 2016 specifically 
addressing Medicare’s coverage of diabetes supplies and services, screening for diabetes 
was addressed.  Medicare’s diabetes screening coverage previously allowed screening 
exclusively with a fasting blood sugar and oral glucose tolerance test.  The updated 
version allows for up to two screening tests per year for Medicare insured individuals and 
covers “fasting blood sugar tests and other tests approved by Medicare as appropriate” 
(CMS, 2016, p. 18), dispelling previous language and allowing screening tests beyond a 
48 
 
fasting glucose level and OGTT.  Additional resources were explored to verify equal 
insurance coverage through several other large insurance companies.  Kaiser Permanente 
(2015) also covers fasting blood sugars and hemoglobin A1c tests for screening purposes.  
Cigna (2016) follows the guidelines recommended by the USPSTF (2017), which 
includes the use of the A1c for screening purposes; similar coverage was documented for 
Anthem Blue Cross Blue Shield (Anthem Blue Cross Blue Shield, 2016) and United 
Healthcare (UHC; 2015), although with more limitations.  United Healthcare’s coverage 
of the hemoglobin A1c as a preventative screening test is only covered if the individual 
has a history of hypertension with a sustained blood pressure of 135/80.  
Objective Two 
The second plan objective included a survey of a panel of experts using the 
Delphi method to gather information on the utility of a clinical practice guideline.  The 
expert panel for round one included two physicians, two nurse practitioners, one of which 
was a doctor of nursing practice, and a physician’s assistant--all working in family 
practices.  They were queried about their current screening methods, familiarity of the 
ADA (2017), WHO (2011b), and USPSTF (2017) guidelines and about their suggestions 
to improve diabetes screening practices.  
Participants 
The first round Delphi questionnaire was administered to the providers through 
SurveyMonkey, an internet survey platform that collects and analyzes data from the 
questionnaire and allows the participants’ responses to remain anonymous.  The survey 
consisting of 18 multiple choice, multiple selection, and short answer questions was sent 
to the participants’ email addresses directly from SurveyMonkey. In total, six providers; 
49 
 
two physicians (MD), three nurse practitioners (APRNs and DNP), and one physician’s 
assistant (PA) were invited to participate (see Table 4).  The data were not available for 
review until the survey closed.  Responses were received from 83.3% of the participants 
(5/6) and all five responding participants answered all 18 questions.  The questionnaire 
was open and available for responses for 30 days--opening August 28 and closing 
September 28.  
 
Table 4 
Delphi Questionnaire Round One Participant Demographics 
Participant  Title/Role Type of Practice Area Served 
#1 MD Family Medicine Rural Northern Colorado 
#2 APRN, DNP Family Medicine Rural Eastern Colorado 
#3 PA Family Medicine Rural Eastern Colorado 
#4 MD Family Medicine Rural Northern Colorado 




Results of the first round of the Delphi questionnaire indicated 100% of the 
providers considered impaired fasting glucose levels, relatives with diabetes, and history 
of gestational diabetes when screening for DM.  Eighty percent felt BMI was an 
important consideration and 40% of the surveyed participants felt impaired random 
glucose levels, age, and ethnicity were also important considerations.  One hundred 
percent of the participants’ organizations did not use a clinical guideline to screen for 
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diabetes and one participant reported personally using the CDC’s (2016) clinical practice 
guideline.  Sixty percent of the respondents were familiar with each of the ADA (2017), 
WHO (2011b), and USPSTF (2017) recommendations for diabetes screening.  The 
participants were advised to consider the ADA, WHO and USPSTF recommendations, 
and to discuss which recommendations they preferred and rationale behind their choice 
(see Table 5).  The responses were varied and included responses such as “results of the 
hemoglobin A1c” and “prefer one or more.”  Participants were queried about their 
personal preferences for diabetes screening.  Eighty percent preferred the hemoglobin 
A1c and 20% preferred fasting glucose levels.  None of the respondents preferred random 
glucose levels or the oral glucose tolerance test.  The participants were surveyed with a 
question asking if they felt the patient population at their organization was adequately 
screened for diabetes.  Four of the five responded favorable, stating they were adequately 
screened and one participant responded with “no- some at risk patients refuse screening 






American Diabetes Association, World Health Organization and United States 
Preventative Services Task Force Recommendations: Provider Preference 
 
Participant  Recommendation Preference 
(ADA, WHO or USPSTF) 
Reasoning 
#1 Prefer more than one ADA. More Parameters 
 
#2 ADA ADA seems to be most used by 
endocrinology & is an easy one to 
reference 
 
#3 ADA, WHO Legitimate 
 
#4 USPSTF USPSTF-comprehensive review of 
studies evaluating benefits/harms of 
screening 
 




The participants were additionally questioned about the utility of a clinical 
guideline and if screening/diagnosis would improve if a practice guideline was available 
for use.  Four of the five participants responded with “yes” and one responded with “no- I 
already screen A1c for physicals and patients at risk.”  The provider participants were 
surveyed about the factors they felt were important to include in a clinical practice 
guideline and if there were a perfect guideline, what components would be included.  The 
participants’ responses included the following: 
• Fasting glucose level 
• A1c 
• Symptoms 
• Past medical history 





• Lab test results 
• Genetic, familial, environmental indications for screening 
• Presence of cardiovascular disease 
• History of gestational diabetes 
• History of elevated lipids 
• All risks 
The final question in the survey requested their recommendations on the format of the 
clinical guideline.  Eighty percent (4/5) preferred a written guideline with an algorithm 
and 20% or one participant preferred a written guideline. 
Objective Two Outcome  
Statements 
The results of the round one Delphi survey indicated a clear need and desire for a 
single clinical practice guideline to assist providers with diabetes screening.  The 
screening methods preferred by the providers as well as consideration of risk factors and 
preferred guideline components were consistent enough to justify the creation of a 
clinical practice guideline.  Given the similarity in the participants’ responses, the 
creation of a clinical guideline simplistic enough to be used by all family practice 
disciplines, containing the elements surveyed as important to the providers, and 







Objective three included the creation of the clinical guideline utilizing the current 
literature, data collected from the retrospective study, and the expert opinions of the 
participants in the first round of Delphi questionnaires.  The feedback from the providers 
who participated in the Delphi survey played an essential role in the construction of the 
clinical guideline.  Expert opinion was necessary to ensure the clinical guideline was user 
friendly and contained components important to the providers who will utilize the clinical 
guideline.  The second part of objective three included a second round Delphi 
questionnaire designed to query the same group of participants about the usefulness of 
the clinical guideline and ensure the components they felt were important were included 
in the algorithm and written guideline.  Because the majority of queried providers 
preferred the elements included in the ADA’s (2017) recommendations, the ADA 
recommendations provided the foundation for the development of the clinical guideline.  
Elements of Guideline 
In addition to ensuring the clinical guideline for this capstone project included the 
research from the literature review, data from the retrospective chart review and expert 
opinion garnered from the first round of Delphi questionnaire, insurance coverage for 
diabetes screening was also considered.  As previously addressed, most of the larger 
insurance companies and Medicare cover diabetes screening as part of a wellness or 
preventative visit.  The clinical practice guideline was comprised of a suggested 
algorithm, overview, and procedure including recommendations dependent on the results 





To ensure adequate insurance coverage for the patient and provider 
reimbursement, the ICD-10 code Z00.00 (encounter for general medical examination 
without abnormal findings) or code Z00.01 (encounter for general medical examination 
with abnormal findings) should be used (NuMed ICD-10 Lookup, n.d.).  Screening labs 
including a fasting blood glucose level should be drawn prior to exam or during the 
wellness visit.  A lipid panel could also be drawn to further stratify the patient’s risk for 
developing Type 2 diabetes beginning at age 35 in men and 45 in women (Siu, 2015).  
Adults over the age of 40 can have a screening A1c drawn, per the USPSTF 
recommendations (Siu, 2015), which are followed by Anthem Blue Cross Blue Shield 
(2016), Cigna (2016) and United Healthcare (2015) with an additional hypertension 
diagnosis using ICD-10 code Z13.1 (diabetes screening; NuMed ICD-10 Lookup, n.d.).   
Adults between the ages of 18 and 44 who have an impaired or abnormal fasting 
blood glucose level and have one additional risk factor should also be screened with a 
hemoglobin A1c using ICD-10 code R73.09 for abnormal FPG or ICD-10 code R73.01 
for impaired FPG (NuMed ICD-10 Lookup, n.d.).  An informal risk assessment should be 
used in adults ages 18-44 to assist with risk stratification and appropriate use of the 
hemoglobin A1c as a screening and diagnostic tool in the diagnosis of Type 2 diabetes 
(WHO, 2011a).  Individuals in this age group with an impaired fasting glucose level and 
one of the following additional risk factor should be routinely screened with an A1c: 
• Impaired Fasting Glucose (100-125 mg/dL) 
• Impaired Random Glucose (126-199 mg/dL) 
• BMI ≥ 25 
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• Age ≥ 45 
• Native American, Black, Hispanic or Asian Ethnicity 
• Hypertension, hyperlipidemia, or cardiovascular disease 
• Relative with diabetes 
• Personal history of polycystic ovarian syndrome (PCOS) or gestational 
diabetes 
• Physical inactivity. 
Patients with an impaired fasting glucose level should be screened with an A1c if 
they are over the age of 45 or at or under the age of 44 and have one additional risk 
factor.  For individuals with an impaired fasting glucose level and no other additional risk 
factors, age appropriate recommendations and annual fasting glucose levels should be 
followed.  Adults ages 18-44 with an impaired fasting glucose level and normal A1c 
should be screened annually with a fasting blood glucose if no other risk factors are 
present and they have not previously had an impaired fasting glucose level and an A1c 
every three years.  Individuals with at least one additional risk factor regardless of age 
should have an A1c repeated every three to six months until it becomes abnormal or 
repeated glucose levels fall within the normal range.  Individuals with an elevated 
hemoglobin A1c should be diagnosed with prediabetes or diabetes, managed 
appropriately, and retested with an A1c in three to six months.  Adults over the age of 45 
with normal fasting glucose and A1c levels should have annual fasting blood work 
including a lipid panel.  Hemoglobin A1c testing should be repeated every three years.  
The clinical guideline also contains a statement suggesting patients with 
hemoglobinopathies be screened with a two-hour glucose tolerance test instead of the 
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A1c.  The algorithm offers two clinical pathways depending on age and covers all major 
elements addressed in the written clinical guideline on a single page for convenience and 
accessibility. 
Results of the Round Two Delphi  
Questionnaire 
Round two of the Delphi questionnaire asked the participants to study and 
evaluate the quality of the proposed Diabetes Screening in Adults Clinical Practice 
Guideline and Algorithm.  The second Delphi questionnaire was administered to the 
same panel of expert providers as the first-round questionnaire excluding the one 
participant who did not respond to the invitation for the first survey.  The participants 
were given two weeks to complete the second survey and were queried about the utility 
and comprehensiveness of the proposed clinical guideline.  The participants were asked 
eight “yes” or “no” questions with the goal to obtain at least 70% consensus on the 
comprehensiveness and practical use of the proposed guideline and algorithm.  
Participants were also encouraged to comment on each of the eight questions and to offer 
their opinions about insurance coverage and reimbursement if the clinical practice 
guideline was used. 
 Five of the original participants were invited to complete the second round of 
surveys and four of the five finished the questionnaire (80%).  The results were 
unanimously in favor of the quality and comprehensiveness of the clinical guideline with 
one question providing the only exception: “Looking at the written clinical guideline 
only, do you feel it is easy to follow?”; 75% of the participants responded “yes” (3/4) and 
one participant answered “no” with the following statement: “Algorithms are always 
easier to follow.”  Included in the second round of questionnaires were questions about 
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insurance coverage and reimbursement.  All of the provider experts felt the clinical 
practice guideline was supportive enough to ensure coverage through the largest 
insurance providers.  A table was included on both the algorithm and written guideline 
listing the aforementioned specific diabetes risk factors to consider for the informal 
assessment process.  Again, all provider participants felt the table was helpful.  Question 
7 on the survey asked the participants,  
The written guideline offers a statement about the use of the hemoglobin A1c in 
patients with sickle cell disease and other hemoglobinopathies (pregnancy, 
hemodialysis, recent transfusion or erythropoietin therapy).  Were you aware the 
2-hour glucose tolerance test is the preferred screening method in this population? 
   
Surprisingly, all of the providers answered “no” to this question, indicating a strong need 
for additional education on hemoglobinopathies and use of the A1c. 
Objective Three Outcome  
Statements 
The creation of the Diabetes Screening in Adults Clinical Practice Guideline and 
Algorithm proved to be a challenging and worthwhile undertaking.  The results of the 
second Delphi survey indicated the guideline and algorithm contained the elements 
important to the providers, the recommendations of the ADA (2017), and data supported 
by the literature review and retrospective study conducted for this project.  Participant 
provider experts in the Delphi study felt the guideline and algorithm were easy to use and 
comprehensive, supporting the objective in the guideline development process.  
Objective Four 
The plan for implementation was the fourth objective for this DNP capstone 
project.  Physical implementation was not a defined goal of this objective; however, 
objective four included providing the staff at PAMG with the final clinical practice 
58 
 
guideline for utilization.  No formal training was provided as the guideline is 
comprehensive and the results of the Delphi survey did not indicate a need for additional 
training.  The providers were sent the guideline with instructions to contact this 
researcher with any questions.  If the providers at PAMG decide to implement the 
diabetes screening clinical practice guideline, a second retrospective study is 
recommended to evaluate pre- and post-implementation results and edit as clinically 
necessary or as new evidence dictates. 
Facilitators and Barriers to Project Objectives 
Key Facilitators 
A key advantage to the completion of this capstone project was the ability to use 
the EMR system at PAMG.  The comprehensive retrospective study portion of this 
project would not have been possible without the use of the EMR.  The EMR allowed the 
researcher to search for individuals who visited the clinic during a specific period of time 
for a wellness visit.  Additionally, the utilization of the EMR promoted the ability to 
examine past medical history and co-morbidities, all which were invaluable in the risk 
stratification of the patient population at PAMG.  A second key facilitator to this project 
was the change made internally to the screening processes in 2017 at PAMG.  The 
practice of routinely screening adult patients seen for a wellness visit or had multiple risk 
factors allowed the researcher to contrast the difference screening with a hemoglobin A1c 
made in the same patient population from 2016 when the providers were not routinely 
screening with an A1c to 2017.  A third key facilitator was the support and participation 
from the providers who completed rounds one and two of the Delphi questionnaire.  The 
responses from the provider participants helped focus the development of the clinical 
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practice guideline into an evidence-based, simplistic, and user-friendly tool for diabetes 
screening in family practice. 
Using the Delphi method to query provider participants through SurveyMonkey 
was beneficial in facilitating the completion of project objectives.  The responses 
remained anonymous; thus, the integrity of the questionnaire results was not questioned.  
Providing anonymity for the participants might have played a role in the willingness of 
providers to participate.  Over 80% of the providers invited to participate completed the 
surveys.  The SurveyMonkey website application analyzed the results from the Delphi 
surveys, taking away some of the data analysis process that was cumbersome.  The risk 
of data analysis errors was also eliminated with the use of SurveyMonkey’s services. 
Key Barriers 
Time was the most prominent barrier to the completion of this capstone project.  
Objective four included the actual implementation of the guideline, which was not 
completed for this project due to time constraints.  Following the implementation from 
infancy to one-year post-initiation would have allowed the researcher to perform a post-
implementation study to observe the effects of the guideline on the practice, providers, 
and patient population.  Improvements would have been made to the guideline to ensure 
it continues to be valuable in evidence-based diabetes screening practices.  A second 
barrier to the objectives, although also beneficial, was the change to the diabetes 
screening practices within PAMG to include screening with a hemoglobin A1c in 2017.  
Because a large portion of the proposed clinical practice guideline included screening 
with an A1c at various intervals, the effectiveness of the utilization of the guideline on 
the providers and patient population could be questioned.  Park Avenue Medical Group is 
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also a small practice in a rural area with only two providers.  The effects of diabetes 
screening with the implementation of the guideline created for this project might be 
improved if piloted with a larger family practice. 
Unintended Consequences 
No notable unintended consequences were observed as a result of the completion 
of the DNP project objectives; however, the seventh question in round two of the Delphi 
questionnaire indicated more provider education is necessary on specific 
hemoglobinopathies and the use of the A1c, not only for screening purposes but also for 
diabetes management.  None of the four participants were aware the hemoglobin A1c 
should not be used on certain populations with accuracy; the two-hour OGT test is the 
















Information garnered from the review of literature described the lack of 
congruency in diabetes screening practices nationwide.  The recommendations made by 
the ADA (2017), WHO (2011b), and USPSTF (2017) are all remarkably similar and 
evidence-based, yet rarely used.  While there is no clear answer as to why family practice 
providers are not following the diabetes screening recommendations made by one or all 
three organizations, the results of this project’s Delphi questionnaire indicated a strong 
desire to have a single clinical practice guideline to follow within their organizations.  
Phase four of this project using the Stetler (2001) model was to physically implement the 
clinical guideline.  The following recommendations are provided in lieu of the physical 
implementation as it was not part of this capstone project.  
Recommendations 
Results of the literature review, retrospective study, and Delphi surveys supported 
the need for a practical tool for diabetes screening in family practice; therefore, it is the 
researcher’s recommendation to move forward with the project.  The clinical practice 
guideline was provided to the providers at PAMG to support their current screening 
practices.  The timeframe to implement the guideline if desired at PAMG will be left to 
the providers’ discretion.  The diabetes screening guideline was created to be 
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comprehensive enough to include the recommendations of the ADA (2017), WHO 
(2011b), and USPSTF (2017), the literature review, and include the preferences of the 
providers obtained through the results of the Delphi surveys.  Very little training is 
required to follow the guideline; however, it is the researcher’s recommendation that new 
providers and students be trained on its application to ensure proper use, insurance 
coverage, and reimbursement.  Periodic review of the ADA, WHO, and USPSTF 
recommendations are recommended to ensure the clinical practice guideline is congruent 
with the latest evidence-based research.  If no changes are made to the guideline, the 
researcher recommends an informal retrospective study to ensure this high-risk 
population is adequately screened for diabetes and changes are made appropriately.  
Consistent adherence to the guideline and algorithm will be necessary to adequately 
assess the usefulness of the clinical practice guideline. 
As education continues to move toward evidence-based models of study, the 
researcher recommends disseminating the clinical practice guideline to other primary care 
providers, students, and educational institutions if the information contained in the 
practice guideline remains current.  Because it is evidence-based and comprehensive 
enough to include recommendations from the ADA (2017), WHO (2011b), and USPSTF 
(2017), it could be used as a practical tool for understanding current standards of practice.  
It is the desire of the researcher for the community of family practice providers to screen 
and treat diabetes aggressively to decrease the complications and comorbidities of a 
diabetes diagnosis.  While the cardiovascular and end organ damaged caused by DM is 
irreversible, Type 2 diabetes is one of the few chronic diseases that is reversible.  Early 
screening and appropriately diagnosing patients with prediabetes allow for initiation of 
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lifestyle modifications and behavioral therapy before irreversible physiological damage 
ensues.  Medicare now covers diabetes self-management training for newly diagnosed 
diabetics, diabetics with other risk factors, or poorly managed diabetics.  The coverage 
allows up to 10 hours of initial training and two additional hours annually if indicated and 
teaches patients how to successfully manage their diabetes.  Diabetes self-management 
training must be prescribed by a provider and can be completed at many federally 
qualified health centers (CMS, 2016).  Finally, intensive diabetes education is 
recommended for patients at risk for developing diabetes as well as newly diagnosed 
prediabetics and diabetics.  Educating patients is empowering; with empowerment, 
providers can help control the information their patients receive, ensure it is accurate, and 
limit the amount of bad information received from other sources.  This could effectively 
place patients in control of their health and lifestyle choices.  
Ongoing Evaluations Necessary for Phases Outside the  
Scope of the Doctor of Nursing Practice Project 
 
Phase five of the Stetler (2001) model addresses the evaluation of the 
intervention.  The evaluation process does not need to be completed formally and should 
include a cost-benefits analysis (Stetler, 2001).  Since this capstone project does not 
cover implementation or evaluation, it would be of value for the staff at PAMG to 
consider re-evaluating the effectiveness of the diabetes screening guideline after an 
informal pilot study.  Costs associated with additional blood work, insurance 
reimbursement for the facility, and additional out-of-pocket costs absorbed by the 
patients should be examined during the evaluation process.  Strict adherence to the 




Personal Goals and Contributions to  
Advanced Practice Nursing 
Improving the practice of screening for diabetes in primary care was the principal 
goal of this project.  It was the researcher’s vision to uncover something uniquely 
brilliant in the retrospective study that could facilitate more research in diabetes 
diagnostic and screening practices performed in the primary care setting.  While that did 
not occur, the creation of a comprehensive clinical practice guideline that included 
existing research and components of the research completed during this project could be 
used to improve screening practices.  Proper utilization of the clinical practice guideline 
would capture and screen all patients at a high risk for developing Type 2 diabetes.  The 
specific population for which this guideline would be most beneficial is individuals who 
do not have wildly abnormal fasting glucose levels (100-105mg/dL) and a single diabetes 
risk factor.  This population would be screened with an A1c using criteria outlined in the 
guideline created for this DNP capstone project and would have likely been missed using 
traditional screening methods, thus delaying treatment.  As mentioned previously, 
prediabetes carries the same cardiovascular risk as diabetes and microvascular changes 
might occur consequentially to unintentional delays in treatment.  In an article by Ghody, 
Shikha, Karam and Bahtiyar (2015), it was suggested even mildly elevated blood glucose 
levels could cause microvascular complications like retinopathy, neuropathy, and 
nephropathy (Ghody et al., 2015).  Engaging at-risk individuals in treatment options 
including lifestyle changes, behavioral modifications, and in some instances 




In recent years, there has been a push for higher degrees of education, especially 
in health care. The Doctor of Nursing Practice was created to address challenges within 
health care and translate knowledge into practice, more specifically evidence-based 
practice.  The knowledge garnered from DNP programs allows advanced practice nurses 
to thrive in leadership roles that improve nursing practice and patient outcomes.  The 
American Association of Colleges of Nursing (AACN; 2006) released a publication 
addressing the essentials of a doctoral education for advanced practice nurses.  Within the 
AACN’s document is the delineation between research-focused doctoral degrees and 
practice-focused.  While both doctoral degrees are rigorous and arduous terminal degrees, 
the practice-focused degrees rely less on theory and more on practical experiences.  The 
DNP capstone project is an integrative, immersion experience that challenges DNP 
candidates to translate knowledge into practice (AACN, 2006).  
The AACN (2006) document includes the following eight competencies that must 
be present for attainment of the Doctor of Nursing Practice degree in addition to specialty 
competencies advanced practices nurses must complete: 
• Essential I: Scientific Underpinnings of Practice.  The scientific 
underpinnings of DNP education reflect doctoral level complexities 
foundational in nursing including a holistic approach to life processes, 
patterns of human interaction with normal life events and the environment, 
and nursing processes that create positive changes (AACN, 2006).  Within 
this essential, doctoral-prepared nurses learn to develop and evaluate new 




• Essential II: Organizational and Systems Leadership for Quality 
Improvement and Systems Thinking.  According to the AACN (2006), a 
DNP graduate who possesses this essential is not only focused on improving 
health outcomes but also understands principles of practice management, 
assesses policies and procedures, and addresses improvement strategies that 
are cost effective and sustainable.  Competency was demonstrated within 
this essential by the ability of this DNP candidate to assess risks and manage 
through collaboration with others using principles of economics, business, 
and healthcare policy.  The final tenet of this competency is accountability.  
The DNP candidate is not only accountable for managing ethical dilemmas 
but also ensures the quality of healthcare delivery (AACN, 2006).  Although 
not always evident, these principles were applied throughout the production 
of the project.  
• Essential III: Clinical Scholarship and Analytical Methods for Evidence-
Based Practice.  This competency is arguably the most important concept of 
a DNP education.  Bridging the gap between knowledge and practice is the 
fundamental tenet of this competency.  A DNP graduate must be able to 
investigate and synthesize data, isolate facts, and make connections that 
hold validity across disciplines (AACN, 2006).  Problem solving is achieved 
through application of knowledge and shared through dissemination of such 
knowledge through projects such as this capstone research project. 
• Essential IV: Information Systems/Technology and Patient Care Technology 
for the Improvement and Transformation of Health Care.  Information 
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systems education and the use of technology to improve healthcare is 
instrumental to DNP education.  The application of information systems and 
technology spans outside the realm of academia and into patient care for 
evaluating quality and safety standards, programs of care, and outcomes of 
care.  This technology is used to perform cost benefits analyses, allow tools 
for budgeting, and evaluate consumer health information (AACN, 2006).  
Application of this essential was demonstrated through the use of internet- 
based research and EMR utilization. 
• Essential V: Health Care Policy for Advocacy in Health Care.  Healthcare 
policy on a broad scale would cover changes in legislation or through other 
government actions; while it is necessary for DNPs to be on the forefront of 
legislative policy changes, the actions of a DNP educated nurse could also 
be witnessed on a smaller scale within organizations.  A DNP graduate is 
often called upon to facilitate changes in healthcare financing, access, 
safety, efficacy, and quality by advocating for policy changes impacting 
social justice and equity in health care.  Demonstrating leadership and 
strength in knowledge of healthcare policy allows the DNP graduate to 
influence and implement change at the institutional, local, state, and national 
and international levels (AACN, 2006). 
• Essential VI: Interprofessional Collaboration for Improving Patient and 
Population Health Outcomes.  The Agency for Healthcare Research and 
Quality (2016) recently mandated six domains of healthcare quality, which 
require a multidisciplinary approach to providing safe, effective, patient-
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centered, timely, efficient, and equitable care.  Doctor of Nursing Practice 
graduates possess a unique set of skills that allow them to effectively 
participate in a collaborative interdisciplinary team and lead when 
appropriate.  Effective communication and collaborative skills allow the 
DNP graduate to lead changes in the delivery of healthcare congruent with 
the AACN’s (2006) goals to improve patient outcomes. 
• Essential VII: Clinical Prevention and Population Health for Improving the 
Nation’s Health.  Population health, health promotion, and disease 
prevention are required coursework for the DNP graduate.  These classes 
place emphasis on promoting health through lifestyle choices and healthcare 
decisions, risk reduction and illness prevention, and improving the health of 
the community.  Many of these skills are taught through evidence-based 
recommendations, social determinants of health, and cultural sensitivity.  
Doctor of Nursing Practice graduates use their knowledge to evaluate care 
delivery models influenced by the community, occupational and 
environmental conditions, as well as socioeconomic and cultural dimensions 
of health to influence changes geared to improve the health of the 
population (AACN, 2006). 
• Essential VIII: Advanced Nursing Practice.  The AACN’s (2006) 
publication acknowledged the complexity of specialization in advanced 
practice nursing.  Doctor of Nursing Practice prepared graduates are all 
specialists in one or several areas, making their contribution to nursing the 
hallmark of the Doctor of Nursing Practice.  Experiential opportunities 
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gained from each nursing specialty allows the advanced practice nurse to 
assess health and illness parameters in complex situations using a holistic 
approach, implement therapeutic interventions based on nursing sciences, 
create and maintain relationships with patients and other disciplines, and 
guide and mentor other nurses to uphold excellence in care delivery 
(AACN, 2006).  Evidence-based care delivery models are fundamental to 
nursing practice and are encouraged throughout all levels of nursing 
education. 
Summary 
As diabetes continues to grow at epidemic proportions, evidence-based diagnostic 
and screening interventions are necessary to prevent the concurrent physiological damage 
caused by a diabetes diagnosis.  Early screening and detection could help minimize the 
negative effects of the disease by encouraging early treatment interventions.  The 
coherence of recommendations made by the ADA (2017), WHO (2011b), and USPSTF 
(2017) supported the need for more comprehensive screening in the at-risk population.  
Development of a simple, yet comprehensive clinical practice guideline for this DNP 
capstone research project was created to facilitate early detection of diabetes or 
prediabetes to foster interventions aimed at preventing end organ damage and the 
cardiovascular consequences caused by diabetes.  Proper guideline utilization would help 
identify individual risk factors and stimulate diabetes screening to promote early lifestyle, 












Agency for Healthcare Research and Quality. (2016). The six domains of health care 
quality. Retrieved from https://www.ahrq.gov/professionals/quality-patient-
safety/talkingquality/create/sixdomains.html 
American Association of Colleges of Nursing. (2006). The essentials of doctoral 
education for advanced nursing practice. Retrieved from http://www.aac 
nnursing.org/Portals/42/Publications/DNPEssentials.pdf 
Anthem Blue Cross Blue Shield. (2016). Preventive care services covered with no 
member cost share. Retrieved from https://www11.anthem.com/provider/nv/f 
5/s2/t0/pw_g296138.pdf?refer=ahpprovider 
American Diabetes Association. (2013, March 6). Economic costs of diabetes in the U.S. 
in 2012. Diabetes Care, 36(4), 1033-1046. http://dx.doi.org/10.2337/dc12-2625 
Bouchonville, M. F., Matani, S., DuBroff, J. J., & DuBroff, R. J. (2017). Are diabetes 
guidelines truly evidence based? Diabetes Research and Clinical Practice, 127, 
71-79. http://dx.doi.org/10.1016/j.diabres.2017.02.035 
Bowen, M. E., Xuan, L., Lingvay, I., & Halm, E. A. (2017). Performance of a random 
glucose case-finding strategy to detect undiagnosed diabetes. American Journal of 





Cefalu, W. T. (Ed.). (2017, January). American Diabetes Association: Standards of 
medical care in diabetes-2017. Diabetes Care, 40(Supp. 1), S1-S135.  
http://dx.doi.org/10.2337/dc17-S001 
Centers for Disease Control and Prevention. (2014). National diabetes statistics report: 
Estimates of diabetes and its burden in the United States, 2014 [Press release]. 
Retrieved from https://www.cdc.gov/diabetes/pubs/statsreport14/national-
diabetes-report-web.pdf 
Centers for Medicare and Medicaid Services. (2016). Medicare’s coverage of diabetes 
supplies and services [Press release]. Retrieved from https://www.medicare.gov/ 
Pubs/pdf/11022-Medicare-Diabetes-Coverage.pdf 
Cigna. (2016). Type 2 diabetes: Screening for adults. Retrieved from https://www.cigna. 
com/healthwellness/hw/medical-topics/type-2-diabetes-zj1182 
Colorado Department of Public Health and Environment. (2015, November). Diabetes’ 
impact in Colorado [Press release]. Retrieved from 
https://www.colorado.gov/pacific/sites/ default/files/ 
DCFactsheet_Facts_For_Action_Diabetes_In_Colorado_November _2015.pdf 
Corriere, M. D., Minang, L. B., Sisson, S. D., Brancati, F. L., & Kalyani, R. R. (2014). 
The use of clinical guidelines highlights ongoing educational gaps in physicians’ 






De Belvis, A. G., Pelone, F., Biasco, A., Ricciardi, W., & Volpe, M. (2009). Can primary 
care professionals’ adherence to evidence based medicine tools improve quality of 
care in type 2 diabetes mellitus? A systematic review. Diabetes Research and 
Clinical Practice, 85, 119-131. http://dx.doi.org/10.1016/j.diabres.2009.05.007 
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008, November). 
Epidemiology of diabetes and diabetes-related complications [Special Issue]. 
Physical Therapy, 88(11), 1254-1264. http://dx.doi.org/10.2522/ptj.20080020 
Ghody, P., Shikha, D., Karam, J., & Bahtiyar, G. (2015). Identifying prediabetes-Is it 
beneficial in the long run? Maturitas, 81, 282-286. 
https://doi.org/10.1016/j.maturitas.2015.03.022 
Glasgow, R. E., McKay, H. G., Piette, J. D., & Reynolds, K. D. (2001). The RE-AIM 
framework for evaluating interventions: what can it tell us about approaches to 
chronic illness management? Patient Education and Counseling, 44, 119-127. 
https://doi.org/10.1016/s0738-3991(00)00186-5 
Imagawa, A., & Hanafusa, T. (2006). Pathogenesis of fulminant type 1 diabetes. The 
Review of Diabetic Studies, 3(4), 169-177. 
http://dx.doi.org/10.1900/RDS.2006.3.169 







Khunti, K., Mani, H., Achana, F., Cooper, N., Gray, L. J., & Davies, M. J. (2015, 
September 1). Systematic review and meta-analysis of response rates and 
diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. 
PLOS One, 10(9), 1-19. http://dx.doi.org/10.1371/journal.pone.0135702 
MacArthur, C. (2015). Ketoacidosis in diabetes: Recognition and avoidance. Practice 
Nursing, 26(8), 393-399. http://dx.doi.org/10.12968/pnur.2015.26.8.393 
NuMed ICD-10 Lookup. (n.d.). ICD-10 codes. Retrieved from https://www.nuemd.com/ 
icd-10/codes/ 
Palmiere, C., Bardy, D., Mangin, P., & Werner, D. (2013). Postmortem diagnosis of 
unsuspected diabetes mellitus. Forensic Science International, 226, 160-167. 
http://dx.doi.org/10.1016/j.forsciint.2013.01.004 
Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R. (2015, June 2). 
Screening for type 2 diabetes mellitus: A systematic review for the U.S. 
Preventative Services Task Force. Annals of Internal Medicine, 162(11), 765-776. 
http://dx.doi.org/10.7326/M14-2221 
Siu, A. L. (2015, December). Screening for abnormal blood glucose and type 2 diabetes 
mellitus: U.S. Preventative Task Force recommendation statement. Annals of 
Internal Medicine, 163, 861-869. http://dx.doi.org/10.7326/M15-2345 
Stetler, C. B. (2001, November/December). Updating the Stetler model of research 
utilization to facilitate evidence-based practice. Nursing Outlook, 49(6), 272-279. 
http://dx.doi.org/10.1067/mno.2001.120517 




U.S. Preventative Services Task Force. (2017). Grade definitions. Retrieved from 
https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions 
World Health Organization. (2011a). HbA1c in the diagnosis of type 2 diabetes: A 
systematic review [Publication]. Retrieved from http://www.who.int/diabetes/ 
publications/ sys_rev_hbA1c_web.pdf?ua=1 
World Health Organization. (2011b). Use of glycated hemoglobin (HbA1c) in the 
diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation 
[Annual Report]. Retrieved from http://www.who.int/diabetes/publications/report-
hba1c_2011.pdf?ua=1 











































































ROUND ONE DELPHI SURVEY AND CONSENT FORM  





Phase One: Delphi Study, Round One Questionnaire 
 
The following questionnaire will take approximately 10 – 15 minutes to fill out.    
If you think that a colleague would be interested in filling out this questionnaire, please feel free forward 
to them the introductory email about this study. 
1.  What is your current title or role? (You may indicate more than one if applicable) 
MD_____ DO _____ APRN _____ PA_____ 
 
2.  In what kind of practice do you primarily work? 
Family Medicine   _____ 
Internal Medicine _____ 
 
3.  What ages of patients do you primarily see? (You may indicate more than one) 
Children (Birth to 12) _____          Adolescents (13-18) _____          Adults (19-39) _____ 
Adults (40-64) _____ Older Adults (>65) _____ 
 
4.  What area do you primarily serve? 
Denver Metro _____ 
Rural Northern Colorado _____ 
Rural Eastern Colorado _____ 
Other _____  Please Name _______________________________________________________________ 
_____________________________________________________________________________________ 
 
5.  Which risk factors do you consider when screening for diabetes? 
Impaired fasting blood sugar _____          Impaired random blood sugar _____          Age _____ 
BMI _____          Gender _____          Ethnicity _____          Blood pressure _____          
Relative with diabetes _____          History of gestational diabetes _____          Physical inactivity _____ 
History of polycystic ovarian syndrome _____          History of cardiovascular disease _____           
Other _____ (please list) ________________________________________________________________ 
6.  Do providers at your location utilize any clinical guidelines pertaining to the screening/diagnosis of 
diabetes? 
Yes  ________     No  ______ 





7.  Do you follow any specific clinical practice guideline pertaining to the screening/diagnosis of diabetes? 
No _____ 
Yes _____  If so, which do you use (please name) ________________________________________ 
 
8.  Are you familiar with any of the following diabetes screening recommendations? 
American Diabetes Association (Updated 1/2017)? _____ 
World Health Organization (Updated 2016)? _____ 
United States Preventative Services Task Force (Updated 12/2015)? _____ 












If you prefer to follow parts of one or more of the above standard guidelines please elaborate (if possible 












10.  Which method do you prefer for screening for diabetes? 
Fasting blood sugar _____ 
Random blood sugar _____ 
Hemoglobin A1c _____ 
Oral glucose tolerance test _____ 
Other _____ (please name) ______________________________________________________________ 
 






12. Do you feel the patient population at your organization is adequately screened for diabetes? 
Yes _____ 
No  _____ 






13.  If a comprehensive diabetes screening clinical guideline were available to you or other providers in 
your organization, do you think it would improve or increase screening/diagnosis practices? 
Yes _____ 
No  _____ 






14.  What guideline format do you prefer? 
Written guideline _____ 
Algorithm only _____ 
Guideline with an algorithm  _____ 



















American Diabetes Association Recommendations 2017 
 
Test Value Description  
Fasting Plasma Glucose ≥ 126 mg/dL Fasting is defined as no caloric 
intake for > 8 hours 
2-hour Plasma Glucose ≥ 200 mg/dL Using WHO guidelines and 
glucose load of at least 75 g of 
anhydrous glucose 
A1c ≥ 6.5% Lab tested using method that is 
NGSP certified and standardized 
Random Plasma Glucose ≥ 200 mg/dL With classic symptoms of 
hyperglycemia 
 
The diagnosis of diabetes is made only after repeat confirmation, unless there is a clear clinical diagnosis of 
random plasma glucose level ≥ 200 mg/dL in a symptomatic individual (polyuria, polyphagia, polydipsia). 
The second test should be conducted as soon as possible and questionable results should be repeated in 3-6 
months. 
Screen overweight or obese individuals (BMI>25) with one or more risk factors (A1c ≥ 5.7%, impaired 
glucose tolerance test (IGT), impaired fasting glucose level (IFT), 1st degree relative with type 1 DM, high 
risk ethnicity, women with history of gestational DM, history of cardiovascular disease, hypertension, 
history of PCOS or other diseases causing insulin resistance, physical inactivity) 
Routine testing for everyone beginning at age 45 and repeated every 3 years for individuals with normal 
results.   
More frequent testing is recommended based on risk stratification and prediabetes status.  




World Health Organization Recommendations 2016 
 
 
Diagnosis of DM in an asymptomatic individual: 
Should not be based on a single abnormal plasma glucose or A1c level. 
A second test with values within the diabetic range is a requirement for diagnosis according to the WHO 
standards using fasting, random or oral glucose tolerance testing in a stringently controlled testing or lab 
environment. 
Periodic retesting is recommended for individuals having a singular positive diagnostic test and negative 




Fasting Plasma Glucose  ≥ 7.0 mmol/L (126 mg/dl) 
2-hour Plasma Glucose ≥ 11.1 mmol/L (200 mg/dl) 
HbA1c ≥ 6.5% 
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United States Preventative Services Task Force Recommendations 2015 
 
Test Value 
Hemoglobin A1c Level ≥ 6.5% 
Fasting Plasma Glucose Level ≥ 7.0 mmol/L 
≥ 126 mg/dl 
2-hour Oral Glucose Tolerance Test ≥ 11.1 mmol/L 




Screen only adult patients ages 40-70 who are asymptomatic and overweight or obese. 
Screen individuals with additional at least one risk factors such as family history of diabetes, history of 
gestational diabetes, polycystic ovarian syndrome, or persons of high risk ethnicities earlier. 
Screening Tests: 
HbA1c 
Fasting plasma glucose level 
Oral glucose tolerance test 
Screening Interval: 
Every 3 years for initial normal levels 
Annual Risk assessment to identify risk factors for abnormal glucose metabolism such as obesity, physical 
inactivity, smoking, hypertension and hyperlipidemia 
Diagnosis: 





CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH 
UNIVERSITY OF NORTHERN COLORADO 
 
INFORMED CONSENT-NO SIGNATURE DOCUMENT 
 
Project Title: Screening for Diabetes in At-Risk Populations in Primary Care 
 
Student Researcher: Vera L. Pillitteri, BSN, RN, DNP-S 
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM, School of Nursing 
Co-Research Advisor: Vicki Wilson, PhD, MS, RN, School of Nursing 
Committee Member: Deborah Green, M.D. 
 
Expert Consensus: A Delphi Study 
 
 
The purpose of the following Doctor of Nursing Practice Research Translation Project is 
to develop an evidence-based clinical practice guideline for improved screening methods 
in the diagnosis of diabetes in the adult population with one or several risk factors, or 
those individuals considered to have an increased risk for the development of type 2 
diabetes. Evaluation of current screening practices in the family practice setting will be 
conducted.  Participation from advanced practice healthcare providers throughout 
Colorado will be requested to develop expert consensus in the creation of a user friendly 
and simplistic clinical practice guideline.    
 
The Delphi Method originally developed in the 1950’s is a widely used research tool for 
surveying expert opinion and consensus on a specific topic or field of study using a 
questionnaire.  The Delphi method was created to address what could or should be done 
in practice and has been fundamental in the development of clinical guidelines.  For the 
purposes of this project, two rounds of questioning will be administered to the panel of 
experts (participants), first addressing observed or utilized diabetes screening practices 
using the Delphi Method.  The second round of questions will address the proposed 
screening guideline, ease of use and prospective utilization.  It is anticipated that each 
participant will complete each round of the Delphi survey in under 20 minutes.  Two 
rounds of questioning will be required for this capstone project. 
 
The responses gathered from the surveyed material will be recorded anonymously and 
only the student researcher and the research advisor will have access to the original 
responses.  All Delphi questionnaires will be sent and returned electronically through 
private email on a secure server.  Participation is voluntary and all responses will be 
kept anonymous.  The responses will be kept on a password protected USB flash drive 
and in the possession of the DNP student.  Access will only be granted to the student 
researcher and research advisor.  Since participation is voluntary and this is a quality 
improvement project, there are no foreseeable risks to the participants. 
 
Participation is voluntary. You may decide not to participate in this study and if you 
begin participation you may still decide to stop and withdraw at any time. Your decision 
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will be respected and will not result in loss of benefits to which you are otherwise 
entitled.  If you have questions, please contact a member of the research team.   
 
Having read the above and having had an opportunity to ask any questions, please 
complete the questionnaire “Phase One: Delphi Study, Round One Questionnaire” if you 
would like to participate in this research.  By completing the questionnaire and returning 
it to the student researcher, it will be assumed that you have communicated consent in 
participation. Please print a copy of this form to retain for future reference.  Please return 
the completed survey to verapillitteri@gmail.com 
 
If you have any concerns about your selection or treatment as a research participant, 
please contact Sherry May, IRB Administrator, Office of Sponsored Programs, 25 
Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970-351-1910.  
 












Committee Member: Deborah Green, M.D. 
Address: Park Avenue Medical Group 
   315 Park Avenue 






















SUMMARY AND RESPONSES TO DELPHI  






























































































Phase Three: Delphi Study Round Two Questionnaire 
 
Thank you for your participation in the Delphi Study Round Two Questionnaire.  The 
purpose of this questionnaire is to obtain consensus regarding the proposed clinical 
guideline developed for utilization by the providers at Park Avenue Medical Group.  The 
objective of this guideline is to obtain at least 70% participant consensus on the ease of 
use and clinical utility of the proposed guideline and algorithm. 
The information gathered from the Delphi Study Round One and the results from a 
retrospective chart review utilizing the electronic medical record (EMR) at Park Avenue 
Medical Group were used in conjunction with the current evidence-based 
recommendations to develop the proposed guideline.  The chart review process evaluated 
current screening practices, risk factors identified by the American Diabetes Association, 
World Health Organization and United States Preventative Services Task Force and the 
demographic information on the patient population at Park Avenue Medical Group.  
Additionally, random and fasting blood glucose levels at or above 100 mg/dL were 
considered and utilized to improve sensitivity and specificity of the diabetes screening 
process.  Please use the attached information to answer the following questions. 
1. 100% of the participants responded that impaired fasting blood glucose levels, a 
relative with diabetes or a past history of gestational diabetes are the most 
important factors to consider when screening for diabetes, and BMI (80%), 
impaired random glucose levels, age and ethnicity (40%) were also important 
considerations. Do you feel the attached algorithm adequately considers these 
factors? 
 
Yes _____     No _____ 
If you answered no, what do you feel is missing? 
__________________________________________________________________ 
 
2. 80% of the Phase One participants do not follow any clinical guideline for 
diabetes screening, however prefer the parameters addressed by the American 
Diabetes Association’s recommendations (fasting glucose levels, A1c, symptoms, 
family history, co-morbidities and BMI).  Do you feel the attached algorithm 
correctly reflects the ADA’s recommendations? (See the attached ADA 
recommendations if you are unfamiliar with them). 
 
Yes _____     No _____ 







3. The algorithm utilizes the A1c as a screening method in various stages depending 
on age and risk factors.  Do you feel using the algorithm would allow adequate 
insurance coverage and reimbursement for diabetes screening? 
 
Yes _____     No _____ 
If you answered no, what additional factors should be considered? 
__________________________________________________________________ 
 
4. Looking at the written clinical guideline only, do you feel it is easy to follow? 
 
Yes _____     No _____ 
If you answered no, what areas require clarification? 
__________________________________________________________________ 
 
5. Again, looking at only the written guideline, do you feel Table 1 is helpful? 
 
Yes _____     No _____ 
 
6. Do you feel the inclusion of the ICD 10 codes and CPT codes will be helpful for 
ensuring insurance coverage and reimbursement? 
 
Yes _____     No _____ 
If you answered no, please explain 
__________________________________________________________________ 
 
7. The written guideline offers a statement about the use of the hemoglobin A1c in 
patients with sickle cell disease and other hemoglobinopathies (pregnancy, 
hemodialysis, recent transfusion or erythropoietin therapy).  Were you aware 
the 2-hour glucose tolerance test is the preferred screening method in this 
population? 
 
Yes _____     No _____ 
 
8. Do you have any additional recommendations about the ease of use or 
comprehensiveness of the clinical practice guideline and algorithm? 
 
Yes_____     No _____ 










































































SCREENING FOR TYPE 2 DIABETES IN ADULTS  










CLINICAL PRACTICE GUIDELINE 
 
TITLE: Screening for Type 2 Diabetes Mellitus in the Adult Population Clinical 
Practice Guideline 
Author: Vera L. Pillitteri BSN, RN, DNP-S 
Reviewed: October 2017 
Target Population: All adult patients over the age of 45 and adult patients ages 18-44 
with one or more risk factor 
Rationale: The following practice guideline will assist with differentiating at-risk 
populations and model screening practices for type 2 diabetes mellitus in the primary care 
setting. 
Overview 
Screening for type 2 diabetes has been the focus of ongoing efforts to minimize the 
cardiovascular consequences and long-term effects of diabetes, however there has not 
been consensus on screening practices.  A recent survey indicated that while providers 
are familiar with the American Diabetes Association, World Health Organization and the 
United States Preventative Services Task Force recommendations, they are not being 
used to screen for diabetes in the primary care setting.   
A retrospective study was conducted to evaluate the screening practices and risk 
stratification at a rural family practice. The data was examined to quantify the number of 
diabetes related risk factors in the patient population as well as to analyze screening 
methods used for a wellness visit in diabetic and non-diabetic patients.  The results 
indicated routinely screening with only a fasting blood glucose level would fail to capture 
a significant number of individuals with a normal fasting glucose level and potentially 
elevated hemoglobin A1c results falling within the prediabetes or diabetes range.  
Additionally, individuals with impaired fasting glucose levels were either sent for 
additional testing, did not follow up or were lost to follow up causing a delay in 
treatment.  Based on the data collected in the retrospective chart review, performing both, 
a fasting blood sugar and hemoglobin A1c on all patients during their annual wellness 
visit on adults ages 45 and older, and on adults ages 18-44 with impaired fasting glucose 
levels and one additional risk factor would capture nearly 10 times more patients with the 
potential to have elevated A1c levels.  
The purpose of this practice guideline is to provide a simplistic, yet comprehensive tool 
to assist with screening for type 2 diabetes in the primary care setting using the latest 
research based evidence from the retrospective study as well as the American Diabetes 
Association, World Health Organization and United States Preventative Services Task 
Force. 
Procedure 
For all patients presenting to the clinic for a wellness exam (ICD 10 code Z00.00 or 
Z00.01), screening labs including a fasting blood glucose level should be drawn prior to 
exam or during the wellness visit.  A lipid panel can also be drawn to further stratify the 
individual’s risk for the development of type 2 diabetes. Individuals ages 40 and older 
should additionally have a screening hemoglobin A1c drawn with fasting labs using the 
diabetes screening ICD 10 code Z13.1 and CPT code 82947 for insurance reimbursement.  
Adults ages 18-44 who have an impaired fasting blood glucose level (100-125 mg/dL) or 
abnormal fasting blood glucose level which includes glucose levels less than 60 mg/dL 
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and have at least one of the following additional risk factors should also be screened with 
a hemoglobin A1c using ICD 10 code R73.09 for abnormal fasting glucose level or 
R73.01 for impaired fasting glucose. 
 
Diabetes Related Risk Factors for Informal Risk Assessment 
• Impaired Fasting Glucose (100-125 mg/dL) 
• Impaired Random Glucose (126-199 mg/dL) 
• BMI ≥ 25 
• Age ≥ 45 
• Native American, Black, Hispanic or Asian Ethnicity 
• Hypertension, hyperlipidemia or cardiovascular disease 
• Relative with diabetes 
• Personal history of polycystic ovarian syndrome (PCOS) or gestational 
diabetes 
• Physical Inactivity 
An informal risk assessment using the above mentioned risk factors should be used in 
adults ages18-44 to assist with risk stratification and appropriate use of the hemoglobin 
A1c as a screening and diagnostic tool in the diagnosis of type 2 diabetes.  Individuals 
with an impaired fasting glucose level and one additional risk factor should be routinely 
screened with an A1c.   
Impaired Fasting Glucose Level: Adult individuals with an impaired fasting glucose 
level should be screened with an A1c if they are over the age of 45, or at or under the age 
44 and have one additional risk factor.  For individuals at or under the age of 44 who 
have an impaired fasting glucose level and no other additional risk factors, age 
appropriate recommendations and annual fasting glucose levels should be followed. 
Impaired Fasting Glucose Level and Normal Hemoglobin A1c: Adult individuals ages 
18-44 with an impaired fasting glucose level and normal A1c should be screened 
annually with a fasting blood glucose if no other risk factors are present and they have 
not had an impaired fasting glucose level in the past, and every three years with a 
hemoglobin A1c.  For individuals with at least one additional risk factor, regardless of 
age, an A1c should be repeated every 3-6 months until it becomes abnormal (5.7 or 
higher) or repeated glucose levels fall within the normal range (60-99 mg/dL). 
Abnormal (elevated) Hemoglobin A1c: Adult individuals with an A1c level within the 
abnormal range (5.7 or higher) should be diagnosed with prediabetes or diabetes, 
managed appropriately and retested with an A1c in 3-6 months. 
Normal Fasting Blood Glucose and Hemoglobin A1c Level in the 45 and Older 
Population:  Adults age 40 and older with normal fasting blood glucose levels and 
hemoglobin A1c should have annual fasting blood work including a lipid panel, and a 
hemoglobin A1c should be repeated every three years. 
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Individuals with Sickle Cell Trait or Other Hemoglobinopathies:  Adults with sickle 
cell disease or other disorders of the red blood cells should be screened with the 2-hour 
glucose tolerance test instead of the hemoglobin A1c. 
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